<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Gabapentin add‐on treatment for drug‐resistant focal epilepsy - Panebianco, M - 2021 | Cochrane Library</title> <meta content="Gabapentin add‐on treatment for drug‐resistant focal epilepsy - Panebianco, M - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001415.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Gabapentin add‐on treatment for drug‐resistant focal epilepsy - Panebianco, M - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001415.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001415.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Gabapentin add‐on treatment for drug‐resistant focal epilepsy" name="citation_title"/> <meta content="Mariangela Panebianco" name="citation_author"/> <meta content="Institute of Translational Medicine, University of Liverpool" name="citation_author_institution"/> <meta content="m.panebianco@liverpool.ac.uk" name="citation_author_email"/> <meta content="Sarah Al-Bachari" name="citation_author"/> <meta content="Royal Preston Hospital" name="citation_author_institution"/> <meta content="Jane L Hutton" name="citation_author"/> <meta content="University of Warwick" name="citation_author_institution"/> <meta content="Anthony G Marson" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD001415.pub4" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/01/12" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001415.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001415.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001415.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticonvulsants [administration &amp; dosage, adverse effects, *therapeutic use]; Cyclohexanecarboxylic Acids [*therapeutic use]; Drug Resistant Epilepsy [*drug therapy]; Drug Therapy, Combination [methods]; Epilepsies, Partial [*drug therapy]; Gabapentin [administration &amp; dosage, adverse effects, *therapeutic use]; gamma-Aminobutyric Acid [*therapeutic use]; Intention to Treat Analysis; Patient Dropouts [statistics &amp; numerical data]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001415.pub4&amp;doi=10.1002/14651858.CD001415.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="EBp84H4P";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001415\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001415\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001415\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001415\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa","fr","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001415.pub4",title:"Gabapentin add\\u2010on treatment for drug\\u2010resistant focal epilepsy",firstPublishedDate:"Jan 12, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Epilepsy Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=EBp84H4P&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001415.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001415.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001415.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001415.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001415.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001415.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001415.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001415.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001415.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001415.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1708 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001415.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/full#CD001415-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/full#CD001415-sec-0097"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/full#CD001415-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/full#CD001415-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/full#CD001415-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/full#CD001415-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/full#CD001415-sec-0049"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/full#CD001415-sec-0091"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/appendices#CD001415-sec-0104"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/table_n/CD001415StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/table_n/CD001415StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Gabapentin add‐on treatment for drug‐resistant focal epilepsy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/information#CD001415-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Mariangela Panebianco</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/information#CD001415-cr-0005">Sarah Al-Bachari</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/information#CD001415-cr-0006">Jane L Hutton</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001415.pub4/information#CD001415-cr-0007">Anthony G Marson</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/information/en#CD001415-sec-0110">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 12 January 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001415.pub4">https://doi.org/10.1002/14651858.CD001415.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001415-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001415-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001415-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001415-abs-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001415-abs-0005">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001415-abs-0001" lang="en"> <section id="CD001415-sec-0001"> <h3 class="title" id="CD001415-sec-0001">Background</h3> <p>This is an updated version of the Cochrane Review previously published in 2018.</p> <p>Epilepsy is a common neurological disorder characterised by recurrent seizures. Most people with epilepsy have a good prognosis and their seizures are well controlled by a single antiepileptic drug, but up to 30% develop drug‐resistant epilepsy, especially people with focal seizures. In this review, we summarised the evidence from randomised controlled trials (RCTs) of gabapentin, when used as an add‐on treatment for drug‐resistant focal epilepsy. </p> </section> <section id="CD001415-sec-0002"> <h3 class="title" id="CD001415-sec-0002">Objectives</h3> <p>To evaluate the efficacy and tolerability of gabapentin when used as an add‐on treatment for people with drug‐resistant focal epilepsy. </p> </section> <section id="CD001415-sec-0003"> <h3 class="title" id="CD001415-sec-0003">Search methods</h3> <p>For the latest update, we searched the Cochrane Register of Studies (CRS Web) and MEDLINE (Ovid) on 11 August 2020. CRS Web includes randomised or quasi‐randomised, controlled trials from PubMed, Embase, ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform (ICTRP), the Cochrane Central Register of Controlled Trials (CENTRAL), and the Specialised Registers of Cochrane Review Groups including Epilepsy. We imposed no language restrictions. </p> </section> <section id="CD001415-sec-0004"> <h3 class="title" id="CD001415-sec-0004">Selection criteria</h3> <p>Randomised, placebo‐controlled, double‐blind, add‐on trials of gabapentin in people with drug‐resistant focal epilepsy. We also included trials using an active drug control group or comparing different doses of gabapentin. </p> </section> <section id="CD001415-sec-0005"> <h3 class="title" id="CD001415-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected trials for inclusion and extracted the relevant data. We assessed the following outcomes: seizure frequency, seizure freedom, treatment withdrawal (any reason) and adverse effects. Primary analyses were intention‐to‐treat. We also undertook sensitivity best‐case and worst‐case analyses. We estimated summary risk ratios (RR) for each outcome and evaluated dose‐response in regression models. </p> </section> <section id="CD001415-sec-0006"> <h3 class="title" id="CD001415-sec-0006">Main results</h3> <p>We identified no new studies for this update, therefore, the results and conclusions are unchanged. </p> <p>In the previous update of this review, we combined data from six trials in meta‐analyses of 1206 randomised participants. The overall risk ratio (RR) for reduction in seizure frequency of 50% or more compared to placebo was 1.89 (95% confidence interval (CI) 1.40 to 2.55; 6 studies, 1206 participants; moderate‐certainty evidence). Dose regression analysis (for trials in adults) showed increasing efficacy with increasing dose, with 25.3% (95% CI 19.3 to 32.3) of people responding to gabapentin 1800 mg compared to 9.7% on placebo, a 15.5% increase in response rate (95% CI 8.5 to 22.5). The RR for treatment withdrawal compared to placebo was 1.05 (95% CI 0.74 to 1.49; 6 trials, 1206 participants; moderate‐certainty evidence). Adverse effects were significantly associated with gabapentin compared to placebo. RRs were as follows: ataxia 2.01 (99% CI 0.98 to 4.11; 3 studies, 787 participants; low‐certainty evidence), dizziness 2.43 (99% CI 1.44 to 4.12; 6 studies, 1206 participants; moderate‐certainty evidence), fatigue 1.95 (99% CI 0.99 to 3.82; 5 studies, 1161 participants; low‐certainty evidence) and somnolence 1.93 (99% CI 1.22 to 3.06; 6 studies, 1206 participants; moderate‐certainty evidence). There was no evidence of a difference for the adverse effects of headache (RR 0.79, 99% CI 0.46 to 1.35; 6 studies, 1206 participants; moderate‐certainty evidence) or nausea (RR 0.95, 99% CI 0.52 to 1.73; 4 trials, 1034 participants; moderate‐certainty evidence). Overall, the studies were at low to unclear risk of bias due to information on each risk of bias domain not being available. We judged the overall certainty of the evidence (using the GRADE approach) as low to moderate due to potential attrition bias resulting from missing outcome data and imprecise results with wide CIs. </p> </section> <section id="CD001415-sec-0007"> <h3 class="title" id="CD001415-sec-0007">Authors' conclusions</h3> <p>Gabapentin has efficacy as an add‐on treatment in people with drug‐resistant focal epilepsy, and seems to be fairly well‐tolerated. However, the trials reviewed were of relatively short duration and provide no evidence for the long‐term efficacy of gabapentin beyond a three‐month period. The results cannot be extrapolated to monotherapy or to people with other epilepsy types. Further trials are needed to assess the long‐term effects of gabapentin, and to compare gabapentin with other add‐on drugs. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001415-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001415-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001415-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001415-abs-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001415-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001415-abs-0007">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001415-abs-0002" lang="en"> <h3>Gabapentin as an add‐on for drug‐resistant focal epilepsy</h3> <p><b>Background</b> </p> <p>Epilepsy is a disorder where recurrent seizures (fits) are caused by abnormal electrical discharges from the brain. Evidence from randomised controlled trials (well‐designed clinical trials in which people are allocated at random to test a specific drug, treatment or other intervention) are often used to examine how effective and safe antiepileptic medicines are in people who experience such seizures. This review included 12 studies and data from 2607 people with focal seizures (seizures that occur in just one part of the brain). </p> <p><b>Study characteristics</b> </p> <p>Data from six studies were combined in the analysis. All participants (including adults and children) were previously taking at least one antiepileptic medicine and all were continuing to have seizures. Either gabapentin (an antiepileptic medicine) or a placebo (a tablet that contains no medicine) was added to the medicine regimen. </p> <p><b>Key results</b> </p> <p>The results showed that gabapentin effectively reduced seizures when used as an additional treatment. Compared to a placebo, gabapentin was almost twice as likely to reduce seizures by 50% or more. The most common side effects associated with gabapentin were ataxia (poor co‐ordination and unsteady gait), dizziness, fatigue and drowsiness. </p> <p><b>Quality of the evidence</b> </p> <p>Overall, the quality of evidence was low to moderate as information was not reported for all participants in some of the trials and some of the results were imprecise. Research is needed into the effects of the long‐term use of gabapentin, and to compare gabapentin with other add‐on medicines. </p> <p>The evidence is current to 11 August 2020.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001415-sec-0097" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001415-sec-0097"></div> <h3 class="title" id="CD001415-sec-0098">Implications for practice</h3> <section id="CD001415-sec-0098"> <p>In people with drug‐resistant focal epilepsy, gabapentin has efficacy as an add‐on treatment. Moderate‐certainty evidence for the outcomes from this review suggests that a dose of 1800 mg/day will reduce seizure frequency by at least 50% in 25.3% of people (95% confidence interval 19.3% to 32.3%). Although our results suggest that gabapentin 600 mg has a statistically significant effect on seizure frequency, that effect is small and 900 mg/day would seem a more reasonable initial dose. Regression analyses show no plateau of therapeutic effect and it is likely that optimal doses need to be tested in a more standardised manner and final doses provided so that such results can be included in meta‐analyses in the future. Doses of up to 2400 mg/day are currently recommended in the <a href="./references#CD001415-bbs2-0027" title="British National Formulary. www.bnf.org/.">British National Formulary</a>. </p> <p>Low‐ to moderate‐certainty evidence suggests that dizziness, fatigue and somnolence occurs significantly more often with gabapentin than placebo, although gabapentin is generally well tolerated. </p> </section> <h3 class="title" id="CD001415-sec-0099">Implications for research</h3> <section id="CD001415-sec-0099"> <section id="CD001415-sec-0100"> <h5 class="title">The conduct of future 'add‐on' trials</h5> <p>The striking differences between the intention‐to‐treat, worst‐case and best‐case analyses for 50% responder rates has important implications for the conduct of further 'add‐on' studies. For the intention‐to‐treat analysis in this review, all participants lost to follow‐up or excluded from analyses due to inadequate seizure recording were assumed to be 'non‐responders.' The best‐case and worst‐case analyses, although representing the extreme, test the effect of making that assumption. When large discrepancies are found, as in this case, the accuracy of individual trials and hence this review is challenged. </p> <p>The main problem is that participants having trial treatment withdrawn are no longer followed up. This provides a dataset that allows an explanatory 'on treatment analysis,' but precludes a robust intention‐to‐treat analysis. To minimise this problem, every attempt must be made to follow participants up, even if trial treatment has been withdrawn. This provides the maximum dataset from which analyses other than intention‐to‐treat may be undertaken. </p> </section> <section id="CD001415-sec-0101"> <h5 class="title">Further evaluation of gabapentin as an antiepileptic drug</h5> <p>To further evaluate the place of gabapentin in the armamentarium of available antiepileptic drugs, further studies are required that address the following: </p> <p> <ol id="CD001415-list-0014"> <li> <p>the efficacy and tolerability of add‐on doses of gabapentin higher than 1800 mg/day in people with drug‐resistant focal epilepsy, in clearly specified doses and a clarification as to maximum doses achieved when flexible regimens are employed; </p> </li> <li> <p>the long‐term efficacy and tolerability of add‐on gabapentin beyond three months;</p> </li> <li> <p>how gabapentin compares with other add‐on treatments in drug‐resistant focal epilepsy;</p> </li> <li> <p>the role of gabapentin in childhood epilepsies;</p> </li> <li> <p>how gabapentin compares with other standard antiepileptic drugs, such as sodium valproate in generalised epilepsy, as monotherapy. </p> </li> </ol> </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001415-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001415-sec-0008"></div> <div class="table" id="CD001415-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Gabapentin versus placebo for people with drug‐resistant focal epilepsy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Gabapentin versus placebo for people with drug‐resistant focal epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with drug‐resistant focal epilepsy </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> gabapentin </p> <p><b>Comparator:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Gabapentin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction in seizure frequency of</b> ≥ <b>50%: primary analysis</b><br/>Number of seizures reported in seizure diary </p> <p>Follow‐up: 12–14 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 100</b><br/>(17 to 31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.89</b> <br/>(95% CI 1.40 to 2.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1206<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &gt; 1 indicated outcome was more likely in gabapentin group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment withdrawal</b><br/>Number of participants withdrawn for any reason </p> <p>Follow‐up: 12–14 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 100</b><br/>(8 to 15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b> <br/>(95% CI 0.74 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1206<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &gt; 1 indicated outcome was more likely in gabapentin group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: ataxia</b><br/>Number of participants experiencing ataxia </p> <p>Follow‐up: 12–14 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 100</b><br/>(5 to 20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.01</b> <br/>(99% CI 0.98 to 4.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>787<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &gt; 1 indicated outcome was more likely in gabapentin group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: dizziness</b><br/>Number of participants experiencing dizziness </p> <p>Follow‐up: 12–14 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 100</b><br/>(8 to 23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.43</b> <br/>(99% CI 1.44 to 4.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1206<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &gt; 1 indicated outcome was more likely in gabapentin group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: fatigue</b><br/>Number of participants experiencing fatigue </p> <p>Follow‐up: 12–14 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b><br/>(3 to 13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.95</b> <br/>(99% CI 0.99 to 3.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1161<br/>(5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &gt; 1 indicated outcome was more likely in gabapentin group.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: nausea</b><br/>Number of participants experiencing nausea </p> <p>Follow‐up: 12–14 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b><br/>(4 to 12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> <br/>(99% CI 0.52 to 1.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1034<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &gt; 1 indicated outcome was more likely in gabapentin group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: somnolence</b><br/>Number of participants experiencing somnolence </p> <p>Follow‐up: 12–14 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 100</b><br/>(9 to 23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.93</b> <br/>(99% CI 1.22 to 3.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1206<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &gt; 1 indicated outcome was more likely in gabapentin group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: headache</b><br/>Number of participants experiencing headache </p> <p>Follow‐up: 12–14 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b><br/>(3 to 10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.79</b> <br/>(99% CI 0.46 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1206<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &lt; 1 indicated outcome was more likely in control group.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for risk of bias: four studies had missing data and did not carry out intention‐to‐treat analysis. Best‐case and worst‐case scenario analysis demonstrated that missing data may have impacted on the size of the true treatment effect.<br/><sup>b</sup>Downgraded once for risk of bias: three studies had missing data and did not carry out intention‐to‐treat analysis.<br/><sup>c</sup>Downgraded once for imprecision: one study with small number of effects and wide confidence intervals; concern regarding the confidence in overall effect.<br/><sup>d</sup>Downgraded once for imprecision: two studies with small‐study effects and wide confidence intervals; concern regarding the confidence in overall effect. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001415-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001415-sec-0009"></div> <p>This is an updated version of the Cochrane Review previously published in 2018 (<a href="./references#CD001415-bbs2-0046" title="PanebiancoM , Al-BachariS , WestonJ , HuttonJL , MarsonA . Gabapentin add-on treatment for drug-resistant focal epilepsy. Cochrane Database of Systematic Reviews2018, Issue 10. Art. No: CD001415. [DOI: 10.1002/14651858.CD001415.pub3]">Panebianco 2018</a>). </p> <p>The purpose of this updated Cochrane Review is to summarise the current understanding of the role of gabapentin as an add‐on treatment in focal epilepsy resistant to at least one other antiepileptic drug (AED). </p> <section id="CD001415-sec-0010"> <h3 class="title" id="CD001415-sec-0010">Description of the condition</h3> <p>Epilepsy is a common neurological disorder characterised by recurrent seizures. Most people given a diagnosis of epilepsy have a good prognosis and their seizures will be controlled by treatment with a single AED (<a href="./references#CD001415-bbs2-0040" title="ReynoldsEH , ShorvonSD , GalbraithAW , ChadwickD , DellaportasL , VydelingumL . Phenytoin monotherapy for epilepsy: a long term prospective study, assisted by serum level monitoring, in previously untreated patients. Epilepsia1981;22(4):475-88. [PMID: 6790274]">Reynolds 1981</a>). However, up to 30% will continue to have seizures despite treatment with adequate doses of AEDs, often requiring treatment with a combination (<a href="./references#CD001415-bbs2-0028" title="CockerellOC , JohnsonAL , SanderJW , HartYM , ShorvonSD . Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet1995;346(8968):140-4. [PMID: 7603228]">Cockerell 1995</a>). These people represent a significant therapeutic problem taking into account that up to 2% to 3% of the population will experience epilepsy at some time in their lives (<a href="./references#CD001415-bbs2-0030" title="HauserWA , AnnegersJF , KurlandLT . Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia1993;34(3):453-68. [PMID: 8504780]">Hauser 1993</a>). There is no internationally accepted definition of drug resistance, so, for the purpose of this review, we considered people drug‐resistant if they had focal‐onset seizures (simple focal or complex focal or secondary generalised tonic‐clonic seizures, or a combination of these) and failed to respond to at least one monotherapy AED. </p> </section> <section id="CD001415-sec-0011"> <h3 class="title" id="CD001415-sec-0011">Description of the intervention</h3> <p>Although more than 12 new AEDs have entered the market since 1993, up to 30% of people remain resistant to current treatments. Thus, a concerted effort continues to identify and develop new therapies that will help these people (<a href="./references#CD001415-bbs2-0026" title="Barker-HaliskiM , SillsGJ , WhiteHS . What are the arguments for and against rational therapy for epilepsy?Advances in Experimental Medicine and Biology2014;813:295-308. [PMID: 25012386]">Barker‐Haliski 2014</a>). Pharmacological treatment remains the first choice for controlling epilepsy (<a href="./references#CD001415-bbs2-0035" title="LoscherW . Current status and future directions in the pharmacotherapy of epilepsy. Trends in Pharmacological Sciences2002;23(3):113-8. [PMID: 11879677]">Loscher 2002</a>), although recent decades have seen advances in vagal stimulation (<a href="./references#CD001415-bbs2-0038" title="PanebiancoM , RigbyA , WestonJ , MarsonAG . Vagus nerve stimulation for partial seizures. Cochrane Database of Systematic Reviews2015, Issue 4. Art. No: CD002896. [DOI: 10.1002/14651858.CD002896.pub2]">Panebianco 2015</a>), and surgery (<a href="./references#CD001415-bbs2-0043" title="WestS , NolanSJ , CottonJ , GandhiS , WestonJ , SudanA , et al. Surgery for epilepsy. Cochrane Database of Systematic Reviews2019, Issue 6. Art. No: CD010541. [DOI: 10.1002/14651858.CD010541.pub3]">West 2019</a>). Current first‐line treatment for focal epilepsy includes: lamotrigine, sodium valproate, carbamazepine, oxcarbazepine and levetiracetam. When first‐line medications fail to achieve seizure freedom, add‐on therapy is required. </p> </section> <section id="CD001415-sec-0012"> <h3 class="title" id="CD001415-sec-0012">How the intervention might work</h3> <p>Gabapentin was licensed for add‐on use in the UK in 1993. The mechanism of action is uncertain (<a href="./references#CD001415-bbs2-0036" title="McCleanMJ . Gabapentin. Epilepsia1995;36(Suppl 2):S73-S86. [PMID: 8784216]">McClean 1995</a>). Gabapentin is a structural analogue of the neurotransmitter gamma‐aminobutyric acid (GABA). However, it does cross the blood‐brain barrier and its activities are believed not to be GABA‐related. Gabapentin has a high volume of distribution, is not significantly protein‐bound or metabolised, and does not induce or inhibit hepatic enzymes; thus, it has minimal‐to‐no known interactions with other AEDs. </p> </section> <section id="CD001415-sec-0013"> <h3 class="title" id="CD001415-sec-0013">Why it is important to do this review</h3> <p>In this review, we summarised evidence from randomised controlled trials (RCTs) on the efficacy and tolerability of gabapentin for people with drug‐resistant focal epilepsy in order to aid clinical decision‐making when considering gabapentin as an add‐on treatment within this population. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001415-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001415-sec-0014"></div> <p>To evaluate the efficacy and tolerability of gabapentin when used as an add‐on treatment for people with drug‐resistant focal epilepsy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001415-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001415-sec-0015"></div> <section id="CD001415-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001415-sec-0017"> <h4 class="title">Types of studies</h4> <p>To be included in our review, studies had to meet the following criteria:</p> <p> <ol id="CD001415-list-0001"> <li> <p>RCTs that used an adequate method of concealment of randomisation (e.g. allocation of sequentially sealed packages of medication, sealed opaque envelopes, telephone randomisation); </p> </li> <li> <p>double‐blind trials, in which both participant and clinician treating or assessing outcome were blinded to treatment allocated; </p> </li> <li> <p>placebo‐controlled or alternative AED or range of gabapentin doses used as controls;</p> </li> <li> <p>parallel‐group or cross‐over studies.</p> </li> </ol> </p> </section> <section id="CD001415-sec-0018"> <h4 class="title">Types of participants</h4> <p>People of any age with drug‐resistant focal epilepsy (i.e. experiencing simple focal, complex focal or secondary generalised tonic‐clonic seizures). </p> </section> <section id="CD001415-sec-0019"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD001415-list-0002"> <li> <p>The active treatment group received gabapentin in addition to conventional AED.</p> </li> <li> <p>The control group received matched placebo, different dose of gabapentin or alternative AED in addition to conventional AED. </p> </li> </ol> </p> </section> <section id="CD001415-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD001415-sec-0021"> <h5 class="title">Primary outcomes</h5> <section id="CD001415-sec-0022"> <h6 class="title">Reduction in seizure frequency of 50% or more</h6> <p>We chose the proportion of people with a 50% or greater reduction in seizure frequency in the treatment period compared to the prerandomisation baseline period as the primary outcome. This is commonly reported in this type of study and can be calculated for studies that do not report it from baseline seizure data. </p> </section> <section id="CD001415-sec-0023"> <h6 class="title">Seizure freedom</h6> <p>The proportion of people with complete cessation of seizures during the treatment period. </p> </section> </section> <section id="CD001415-sec-0024"> <h5 class="title">Secondary outcomes</h5> <section id="CD001415-sec-0025"> <h6 class="title">Treatment withdrawal</h6> <p>We used the proportion of people having treatment withdrawn during the treatment period as a measure of global effectiveness. Treatment is likely to be withdrawn due to adverse effects, lack of efficacy, or a combination of both, and this is an outcome to which the person makes a direct contribution. In trials of short duration, it is likely that adverse effects will be the most common reason for withdrawal. </p> </section> <section id="CD001415-sec-0026"> <h6 class="title">Adverse effects</h6> <p> <ol id="CD001415-list-0003"> <li> <p>The proportion of people experiencing the following five common and important adverse effects: </p> <ol id="CD001415-list-0004"> <li> <p>ataxia;</p> </li> <li> <p>dizziness;</p> </li> <li> <p>fatigue;</p> </li> <li> <p>nausea;</p> </li> <li> <p>somnolence.</p> </li> </ol> </li> <li> <p>The proportion of people experiencing the five most common adverse effects if different from a. to e. above. </p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD001415-sec-0027"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001415-sec-0028"> <h4 class="title">Electronic searches</h4> <p>Searches were run for the original review in 1998 and subsequent searches were run in 2000, 2003, 2005, 2007, 2010, 2011, 2012, 2013, 2015, 2016 and March 2018. For the latest update, we searched the following databases on 11 August 2020: </p> <p> <ol id="CD001415-list-0005"> <li> <p>Cochrane Register of Studies (CRS Web), using the strategy shown in <a href="./appendices#CD001415-sec-0105">Appendix 1</a>; </p> </li> <li> <p>MEDLINE (Ovid, 1946 to 11 August 2020) using the strategy shown in <a href="./appendices#CD001415-sec-0106">Appendix 2</a>. </p> </li> </ol> </p> <p>CRS Web includes randomised or quasi‐randomised, controlled trials from the Specialized Registers of Cochrane Review Groups including Epilepsy, the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform (ICTRP). There were no language restrictions. </p> </section> <section id="CD001415-sec-0029"> <h4 class="title">Searching other resources</h4> <p>We reviewed the reference lists of included studies to search for additional reports of relevant studies. </p> </section> </section> <section id="CD001415-sec-0030"> <h3 class="title" id="CD001415-sec-0030">Data collection and analysis</h3> <section id="CD001415-sec-0031"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MP and SAB) independently assessed trials for inclusion. Any doubts were resolved by discussion. </p> </section> <section id="CD001415-sec-0032"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (MP and SAB) independently extracted the following information for each trial using a data extraction sheet. Any discrepancies between the extractions of the two review authors were resolved by discussion. </p> <section id="CD001415-sec-0033"> <h5 class="title">Methodological/trial design</h5> <p> <ol id="CD001415-list-0006"> <li> <p>Method of randomisation and allocation concealment.</p> </li> <li> <p>Method of double‐blinding.</p> </li> <li> <p>Whether any participants had been excluded from reported analyses.</p> </li> <li> <p>Duration of baseline period.</p> </li> <li> <p>Duration of treatment period.</p> </li> <li> <p>Dose(s) of gabapentin tested.</p> </li> </ol> </p> </section> <section id="CD001415-sec-0034"> <h5 class="title">Participant/demographic information</h5> <p> <ol id="CD001415-list-0007"> <li> <p>Total number of participants allocated to each treatment group.</p> </li> <li> <p>Age/sex.</p> </li> <li> <p>Number with focal/secondary generalised seizures.</p> </li> <li> <p>Seizure types.</p> </li> <li> <p>Seizure frequency during the baseline period.</p> </li> <li> <p>Number of background drugs.</p> </li> </ol> </p> <p>Parke Davis sponsored most trials (Pfizer Inc. funded one trial); we asked them to confirm the following information: </p> <p> <ol id="CD001415-list-0008"> <li> <p>method of randomisation;</p> </li> <li> <p>total number randomised to each group;</p> </li> <li> <p>number of participants in each group achieving a 50% or greater reduction in seizure frequency per treatment group; </p> </li> <li> <p>number of participants having treatment withdrawn postrandomisation per treatment group; </p> </li> <li> <p>for those excluded:</p> <ol id="CD001415-list-0009"> <li> <p>the reason for exclusion;</p> </li> <li> <p>whether any of those excluded completed the treatment phase;</p> </li> <li> <p>whether any of those excluded had a 50% or greater reduction in seizure frequency during the treatment phase. </p> </li> </ol> </li> </ol> </p> </section> <section id="CD001415-sec-0035"> <h5 class="title">Outcomes</h5> <p>We recorded the number of participants experiencing each outcome (see <a href="#CD001415-sec-0020">Types of outcome measures</a>) per randomised group. </p> <p>We contacted authors of trials for any missing information.</p> </section> </section> <section id="CD001415-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SAB and JW) independently assessed the risk of bias for each trial using the Cochrane 'Risk of bias' tool as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001415-bbs2-0031" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011</a>). We rated included studies as high risk, low risk or unclear risk on six domains applicable to RCTs: randomisation method, allocation concealment, blinding methods, incomplete outcome data, selective outcome reporting and other sources of bias. </p> <p>We outlined studies failing to meet the criteria to be included in the meta‐analysis in narrative form; statistics for those included in the meta‐analysis are outlined below. </p> </section> <section id="CD001415-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <p>We presented the outcomes as risk ratios (RR) with 95% or 99% confidence intervals (CI). </p> </section> <section id="CD001415-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>We assessed cross‐over studies to determine if they presented suitable data to allow for inclusion in meta‐analysis using either 'paired' results adjusted for the cross‐over design, or first period results. </p> <p>One cross‐over trial did not provide suitable data for inclusion in the meta‐analysis, but was discussed in narrative form (<a href="./references#CD001415-bbs2-0005" title="LeachJP , GirvanJ , PaulA , BrodieMJ . Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry1997;62(4):372-6. [PMID: 9120451]">Leach 1997</a>). </p> </section> <section id="CD001415-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>We sought any missing data from study authors. We carried out intention‐to‐treat (ITT), best‐case and worst‐case analysis to account for any missing data (see <a href="#CD001415-sec-0044">Data synthesis</a>). </p> </section> <section id="CD001415-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical heterogeneity by comparing the distribution of important participant factors among trials (e.g. age, seizure type, duration of epilepsy) and trial factors (e.g. methods of randomisation and blinding, missing data). We examined statistical heterogeneity using a Chi<sup>2</sup> test (P &gt; 0.10) and the I<sup>2</sup> statistic (<a href="./references#CD001415-bbs2-0032" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>). </p> </section> <section id="CD001415-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <section id="CD001415-sec-0042"> <h5 class="title">Protocol versus full study</h5> <p>We requested all protocols from study authors to enable a comparison of outcomes of interest. We intended to investigate any suspected outcome reporting bias using the ORBIT matrix system (<a href="./references#CD001415-bbs2-0033" title="KirkhamJJ , DwanKM , AltmanDG , GambleC , DoddS , SmythR , et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ2010;340:c365. [PMID: 20156912]">Kirkham 2010</a>). </p> </section> <section id="CD001415-sec-0043"> <h5 class="title">Funnel plot</h5> <p>Reporting biases arise when dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD001415-bbs2-0032" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>). We intended to use funnel plots for investigating reporting biases when 10 or more studies were included in a meta‐analysis, with awareness that they have limited power to detect small‐study effects and we planned to seek statistical advice on their interpretation. For this review, we did not produce funnel plots for outcomes as fewer than 10 studies were included in meta‐analyses. </p> </section> </section> <section id="CD001415-sec-0044"> <h4 class="title">Data synthesis</h4> <p>We employed a fixed‐effect meta‐analysis to synthesise the data. Comparisons we carried out included: </p> <p> <ol id="CD001415-list-0010"> <li> <p>intervention group versus controls on seizure reduction;</p> </li> <li> <p>intervention group versus controls on seizure freedom;</p> </li> <li> <p>intervention group versus controls on treatment withdrawal;</p> </li> <li> <p>intervention group versus controls on adverse effects.</p> </li> </ol> </p> <p>We performed separate comparisons for different types of control group (i.e. placebo or active control group) and study characteristics (i.e. cross‐over designed trials) to ensure appropriate combination of data. </p> <p>The preferred estimate was the Mantel‐Haenszel RR. For the outcomes reduction in seizure frequency of 50% of more and treatment withdrawal, we used 95% CIs. For individual adverse effects, we used 99% CIs to make an allowance for multiple testing by using wider CIs. This is not a strict formal adjustment, as the number of individual adverse effects is not known in advance. </p> <p>Our analyses included all participants in the treatment group to which they had been allocated. For the primary efficacy outcome (reduction in seizure frequency of 50% or more), we undertook three analyses. </p> <p> <ol id="CD001415-list-0011"> <li> <p>Primary (ITT) analysis: participants not completing follow‐up or with inadequate seizure data were assumed to be non‐responders. To test the effect of this assumption, we undertook the following sensitivity analyses: </p> <ol id="CD001415-list-0012"> <li> <p>worst‐case analysis: participants not completing follow‐up or with inadequate seizure data were assumed to be non‐responders in the gabapentin group and responders in the placebo group; </p> </li> <li> <p>best‐case analysis: participants not completing follow‐up or with inadequate seizure data were assumed to be responders in the gabapentin group and non‐responders in the placebo group. </p> </li> </ol> </li> </ol> </p> <section id="CD001415-sec-0045"> <h5 class="title">Dose regression analysis</h5> <p>We examined dose‐response relationships using logistic regression (for the five adult trials) and calculated probabilities for the following for differing doses: the percentage of participants having a 50% response; and the difference in the percentage of participants responding to each dose compared to placebo. A binary variable was defined with value 0 if the response was less than 50% and value 1 otherwise. We examined dose‐response relationships using logistic regression, in the framework of generalised linear models, using the package GLIM, with this binary variable as the outcome variable (<a href="./references#CD001415-bbs2-0037" title="McCullaghP , NelderJA . Generalized Linear Models. 2nd edition. London: Chapman and Hall, 1989.">McCullagh 1989</a>). Trial effects (i.e. adjustment for trial‐specific differences) were not included in the regression models as it was generally not possible to do so as some doses are confounded with trials; in other words, the dose was evaluated in only a single trial. As none of the tests for heterogeneity reached a significance level of less than 30%, it seemed reasonable to proceed without trial effects. </p> </section> </section> <section id="CD001415-sec-0046"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We intended to investigate heterogeneity using subgroup analysis of important participant factors among trials (e.g. age, seizure type, duration of epilepsy if deemed appropriate. As there was no important heterogeneity in the meta‐analyses in this review, we conducted no subgroup analysis. </p> </section> <section id="CD001415-sec-0047"> <h4 class="title">Sensitivity analysis</h4> <p>We intended to carry out sensitivity analysis if there were peculiarities between study quality, characteristics of participants, interventions and outcomes. </p> </section> <section id="CD001415-sec-0048"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach, as outlined in the GRADE Handbook (<a href="./references#CD001415-bbs2-0042" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html (accessed prior to 18 November 2020).">Schünemann 2013</a>), to interpret findings, and <a href="./references#CD001415-bbs2-0029" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 2015. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a> software (which imports data from Review Manager 5 software (<a href="./references#CD001415-bbs2-0029" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 2015. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>; <a href="./references#CD001415-bbs2-0039" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>)), to create a 'Summary of findings' table for the primary outcome (reduction in seizure frequency of 50% or more) and secondary outcomes (treatment withdrawal and adverse effects). </p> <p>We created a 'Summary of findings' table for the most important comparison (gabapentin versus placebo). We did not create 'Summary of findings' tables for other comparisons with only a single study contributing to the comparison. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001415-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001415-sec-0049"></div> <section id="CD001415-sec-0050"> <h3 class="title">Description of studies</h3> <section id="CD001415-sec-0051"> <h4 class="title">Results of the search</h4> <p>Updated searches conducted in August 2020 revealed 29 records identified from the databases outlined in <a href="#CD001415-sec-0028">Electronic searches</a>. After removal of three duplicates, 26 records were screened for inclusion in the review. We excluded six clearly irrelevant records and assessed three full‐text articles for eligibility. We did not identify any new studies for this update (<a href="./references#CD001415-bbs2-0004" title="FrenchJ , GlueP , FriedmanD , AlmasM , YardiN , KnappL , et al. Adjunctive pregabalin vs gabapentin for focal seizures: interpretation of comparative outcomes. Neurology2016;87(12):1242-9. [PMID: 27521437]">French 2016</a>), therefore the results and conclusions are unchanged (see <a href="#CD001415-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD001415-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram. Date of search 11 August 2020. RCT: randomised controlled trial." data-id="CD001415-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_n/nCD001415-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram. Date of search 11 August 2020. RCT: randomised controlled trial.</p> </div> </div> </div> </section> <section id="CD001415-sec-0052"> <h4 class="title">Included studies</h4> <p>Overall, the review included 12 studies, six of which contributed to the meta‐analyses. The data from the six remaining studies were not combined in meta‐analyses due to the differences in comparisons investigated. <a href="./references#CD001415-bbs2-0024" title="KwanSY , YiuCH , SuMS . A double blind study of gabapentin in partial seizures. Epilepsia2000;41(Suppl Florence):69. ">Kwan 2000</a> and <a href="./references#CD001415-bbs2-0025" title="ShapiroDY , NordliD , GlauserTA , KnappLE , GreinerM , PurcellTJ , et al. Gabapentin as add-on therapy for refractory partial seizures in children 1–36 months of age: a novel, short-term, placebo-controlled trial. Epilepsia2000;41(Suppl 7):106, Abstract no: 2.065. ">Shapiro 2000</a> are awaiting classification as only abstracts were obtainable, therefore, it was not possible to critique the study design (see <a href="./references#CD001415-sec-0118" title="">Characteristics of studies awaiting classification</a>). </p> <p>There were seven trials that compared gabapentin to placebo (<a href="./references#CD001415-bbs2-0001" title="AnhutH , AshmanP , FeuersteinTJ , SauermannW , SaundersM , SchmidtB . Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia1994;35(4):795-801. [PMID: 8082624]">Anhut 1994</a>; <a href="./references#CD001415-bbs2-0002" title="AppletonR , FichtnerK , LaMoreauxL , AlexanderJ , HalsallG , MurrayG , et al, and the Gabapentin Paediatric Study Group. Gabapentin as add-on therapy in children with refractory partial seizures: a 12 week, multicentre, double blind placebo controlled study. Epilepsia1999;40(8):1147-54. [PMID: 10448830]">Appleton 1999</a>; <a href="./references#CD001415-bbs2-0005" title="LeachJP , GirvanJ , PaulA , BrodieMJ . Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry1997;62(4):372-6. [PMID: 9120451]">Leach 1997</a>; <a href="./references#CD001415-bbs2-0008" title="SiveniusJ , KalviainenR , YlinenA , RiekkinenP . Double blind study of gabapentin in the treatment of partial seizures. Epilepsia1991;32(4):539-42. [PMID: 1907907]">Sivenius 1991</a>; <a href="./references#CD001415-bbs2-0010" title="UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet1990;335(8698):1114-7. [PMID: 1971862]">UK Gabapentin 1990</a>; <a href="./references#CD001415-bbs2-0011" title="US Gabapentin Study Group No 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology1993;43(11):2292-8. [PMID: 8232945]">US Gabapentin 1993</a>; <a href="./references#CD001415-bbs2-0012" title="YamauchiT , KanekoS , VagiK , SaseS . Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study. Psychiatry and Clinical Neurosciences2006;60(4):507-15. [PMID: 16884455]">Yamauchi 2006</a>), two trials that examined two different doses of gabapentin (<a href="./references#CD001415-bbs2-0003" title="FisherRS , SachdeoRC , PellockJ , PenovichPE , MagnusL , BernsteinP . Rapid Initiation of gabapentin: a randomised control trial. Neurology2001;56(6):743-8. [PMID: 11274308]">Fisher 2001</a>; <a href="./references#CD001415-bbs2-0009" title="TomovicM , IlicT , MihajlovicM , JovicicA . Gabapentin as adjuvant therapy in the treatment of refractory partial epilepsy. Vojnosanitetski Pregled1999;56(2):151-6. [PMID: 10437420]">Tomovic 1999</a>), one trial that compared gabapentin to vigabatrin (<a href="./references#CD001415-bbs2-0006" title="LindbergerM , AleniusM , FrisenL , JohannessenSI , LarssonS , MalmgrenK , et al, on behalf of the GREAT Study Investigators Group. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomised, double-blind, dose titration study. Epilepsia2000;41(10):1289-95. [PMID: 11051124]">Lindberger 2000</a>), one trial that compared gabapentin to lamotrigine (<a href="./references#CD001415-bbs2-0007" title="SethiA , ChandraD , PuirV , MallikaV . Gabapentin and lamotrigine in Indian patients of partial epilepsy refractory to carbamazepine. Neurology India2002;50(3):359-63. [PMID: 12391470]">Sethi 2002</a>), and one trial that compared gabapentin to pregabalin (<a href="./references#CD001415-bbs2-0004" title="FrenchJ , GlueP , FriedmanD , AlmasM , YardiN , KnappL , et al. Adjunctive pregabalin vs gabapentin for focal seizures: interpretation of comparative outcomes. Neurology2016;87(12):1242-9. [PMID: 27521437]">French 2016</a>). All participants had drug‐resistant focal epilepsy and were taking at least one monotherapy AED. Pre‐existing AED regimens remained unchanged throughout the study period. All outcome measures included seizure reduction and adverse effects. </p> <p>One parallel trial had a 12‐week prerandomisation baseline period and a 12‐week treatment period of gabapentin 900 mg/day (111 participants) or gabapentin 1200 mg/day (52 participants) or placebo (109 participants) (<a href="./references#CD001415-bbs2-0001" title="AnhutH , AshmanP , FeuersteinTJ , SauermannW , SaundersM , SchmidtB . Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia1994;35(4):795-801. [PMID: 8082624]">Anhut 1994</a>). Study medication was administered three times daily (TDS). Included participants had a minimum of six focal seizures within the baseline period and were aged 12 years or over. Women of childbearing potential on adequate contraception and participants with additional seizure types were also included in this study. </p> <p>One multicentre parallel trial had three phases: six weeks of baseline period, nine weeks of double‐blind dose escalation phase and 12 weeks of double‐blind maintenance phase (<a href="./references#CD001415-bbs2-0004" title="FrenchJ , GlueP , FriedmanD , AlmasM , YardiN , KnappL , et al. Adjunctive pregabalin vs gabapentin for focal seizures: interpretation of comparative outcomes. Neurology2016;87(12):1242-9. [PMID: 27521437]">French 2016</a>). There were two arms: 242 participants randomised to gabapentin (300 mg/day, 600 mg/day, 1200 mg/day, 1500 mg/day and 1800 mg/day) and 242 participants randomised to active control (pregabalin 150 mg/day, 300 mg/day, 450 mg/day and 600 mg/day), but 482 participants (241 in gabapentin group and 241 in pregabalin group) received intended treatment. Participants were adults aged 18 to 80 years. During the nine‐week dose‐escalation phase, the minimum maintenance phase dose was gabapentin 1200 mg/day and pregabalin 300 mg/day TDS. During the 21‐week double‐blind phase, the median doses were gabapentin 1500 mg/day and pregabalin 450 mg/day. </p> <p>The baseline period in one parallel trial was six weeks with a treatment period of 12 weeks (<a href="./references#CD001415-bbs2-0002" title="AppletonR , FichtnerK , LaMoreauxL , AlexanderJ , HalsallG , MurrayG , et al, and the Gabapentin Paediatric Study Group. Gabapentin as add-on therapy in children with refractory partial seizures: a 12 week, multicentre, double blind placebo controlled study. Epilepsia1999;40(8):1147-54. [PMID: 10448830]">Appleton 1999</a>). Gabapentin 600 mg/day to 1200 mg/day was administered TDS and was dependent on the weight of the participant. One hundred and twenty‐eight participants received placebo and 119 participants received gabapentin. Participants were children aged less than 12 years and with a minimum of four seizures during the baseline period. </p> <p>One cross‐over trial was a placebo‐controlled study that did not have a prerandomisation baseline period; however, all participants reported at least four seizures per month for the previous three months (<a href="./references#CD001415-bbs2-0005" title="LeachJP , GirvanJ , PaulA , BrodieMJ . Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry1997;62(4):372-6. [PMID: 9120451]">Leach 1997</a>). There were four treatment arms (gabapentin 1200 mg/day, 1800 mg/day and 2400 mg/day, and placebo each administered on a TDS basis). All participants received all doses/placebo in a cross‐over design with a four‐week washout period between each treatment period. The study recruited 27 participants and analysed 23 participants. </p> <p>One parallel trial had a baseline period of three months in which adults with focal epilepsy experienced four or more seizures a month (<a href="./references#CD001415-bbs2-0008" title="SiveniusJ , KalviainenR , YlinenA , RiekkinenP . Double blind study of gabapentin in the treatment of partial seizures. Epilepsia1991;32(4):539-42. [PMID: 1907907]">Sivenius 1991</a>). Participants received either gabapentin 900 mg/day (16 participants), gabapentin 1200 mg/day (nine participants) or placebo (18 participants). Treatment medication was administered for three months. </p> <p>One parallel trial had a three‐month baseline period where participants had at least one focal seizure per week (<a href="./references#CD001415-bbs2-0010" title="UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet1990;335(8698):1114-7. [PMID: 1971862]">UK Gabapentin 1990</a>). This study had a two‐week initiation phase of gabapentin 600 mg/day or placebo administered TDS, after which 61 participants began a 12‐week treatment period of gabapentin 1200 mg/day TDS and 66 participants received placebo. </p> <p>One parallel trial recruited 306 adults, randomising 53 participants to gabapentin 600 mg/day, 101 participants to gabapentin 1200 mg/day, 54 participants to gabapentin 1800 mg/day and 98 participants to placebo, all administered TDS for 12 weeks (<a href="./references#CD001415-bbs2-0011" title="US Gabapentin Study Group No 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology1993;43(11):2292-8. [PMID: 8232945]">US Gabapentin 1993</a>). The study implemented an initiation period of two to three days of either gabapentin 300 mg/day or 600 mg/day up to the required dose. The baseline period was three months and included people who had a minimum of four focal seizures per month. </p> <p>One trial examining gabapentin versus placebo had a baseline period of 12 weeks and included people who had a minimum of eight focal seizures during baseline (<a href="./references#CD001415-bbs2-0012" title="YamauchiT , KanekoS , VagiK , SaseS . Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study. Psychiatry and Clinical Neurosciences2006;60(4):507-15. [PMID: 16884455]">Yamauchi 2006</a>). Adults were randomised into one of three treatment arms: gabapentin 1200 mg/day (86 participants), gabapentin 1800 mg/day (41 participants) and placebo (82 participants), taken TDS over 12 weeks. </p> <p>Two RCTs were gabapentin dose trials that had no placebo group (<a href="./references#CD001415-bbs2-0003" title="FisherRS , SachdeoRC , PellockJ , PenovichPE , MagnusL , BernsteinP . Rapid Initiation of gabapentin: a randomised control trial. Neurology2001;56(6):743-8. [PMID: 11274308]">Fisher 2001</a>; <a href="./references#CD001415-bbs2-0009" title="TomovicM , IlicT , MihajlovicM , JovicicA . Gabapentin as adjuvant therapy in the treatment of refractory partial epilepsy. Vojnosanitetski Pregled1999;56(2):151-6. [PMID: 10437420]">Tomovic 1999</a>). <a href="./references#CD001415-bbs2-0003" title="FisherRS , SachdeoRC , PellockJ , PenovichPE , MagnusL , BernsteinP . Rapid Initiation of gabapentin: a randomised control trial. Neurology2001;56(6):743-8. [PMID: 11274308]">Fisher 2001</a> compared slow initiation (gabapentin 300 mg on day one, gabapentin 600 mg on day two and then gabapentin 900 mg/day for five days) and rapid initiation of gabapentin (placebo for the first two days followed by gabapentin 900 mg/day for five days). Three hundred and sixty participants were in the slow initiation group and 360 participants were in the rapid initiation dose. There was no baseline period; participants were required to have been taking at least one AED for one month prior to the study and were considered to have inadequate seizure control as defined by the authors. Participants were aged 12 years or older. The trial period was seven days. <a href="./references#CD001415-bbs2-0009" title="TomovicM , IlicT , MihajlovicM , JovicicA . Gabapentin as adjuvant therapy in the treatment of refractory partial epilepsy. Vojnosanitetski Pregled1999;56(2):151-6. [PMID: 10437420]">Tomovic 1999</a> compared gabapentin 900 mg/day versus gabapentin 1200 mg/day administered TDS over 12 weeks. There were nine participants in each group. There was no formal baseline period; participants were considered to have unsatisfactorily controlled seizures while taking at least one first‐line AED for three months prior to the study, as defined by the authors. </p> <p>One trial compared gabapentin to lamotrigine; it had an eight‐week baseline period (<a href="./references#CD001415-bbs2-0006" title="LindbergerM , AleniusM , FrisenL , JohannessenSI , LarssonS , MalmgrenK , et al, on behalf of the GREAT Study Investigators Group. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomised, double-blind, dose titration study. Epilepsia2000;41(10):1289-95. [PMID: 11051124]">Lindberger 2000</a>). All participants had tried no more than two AED monotherapy regimens and were on one AED at the time of study (this had to exclude phenytoin). The study required a minimum seizure frequency of four seizures during an eight‐week baseline period and two or more seizures during the last month. One hundred and two participants (aged 12 to 75 years) received either gabapentin or vigabatrin add‐on treatment. There was a flexible dosing regimen over the subsequent 24 weeks: gabapentin variable dose 1800 mg/day minimum, then 2400 mg/day and then a maximum of 3600 mg/day, increased every eight weeks as tolerated. The vigabatrin initial dose was 1000 mg/day, then 2000 mg/day, then 4000 mg/day, increased in the same manner (as tolerated by adverse effects) and increased if complete seizure freedom was not attained. The total trial period was 24 weeks; however, outcome measures were taken at eight weeks (awaiting clarification from author). </p> <p>One trial compared gabapentin to lamotrigine in participants resistant to the maximum tolerated dose of carbamazepine monotherapy, with a seizure duration of two years or less (<a href="./references#CD001415-bbs2-0007" title="SethiA , ChandraD , PuirV , MallikaV . Gabapentin and lamotrigine in Indian patients of partial epilepsy refractory to carbamazepine. Neurology India2002;50(3):359-63. [PMID: 12391470]">Sethi 2002</a>). Twenty‐seven participants received gabapentin and 25 participants received lamotrigine and were aged 10 to 60 years. Baseline seizure frequency was at least four seizures despite treatment (unclear over what time frame). The baseline period was time of enrolment. The trial period was 12 weeks. Treatment was gabapentin 300 mg on day one, 300 mg twice daily on day two and thereafter an increment of 300 mg/day until seizures were controlled or toxic effects appeared. Lamotrigine was started at 50 mg/day for two weeks, then 50 mg twice daily for two weeks, then increased by 50 mg to 100 mg every two weeks until seizures were controlled or there were toxic effects. </p> <p>For further information on each trial, see the <a href="./references#CD001415-sec-0116" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD001415-sec-0053"> <h4 class="title">Excluded studies</h4> <p>In this update, we excluded three additional studies as they were not RCTs (<a href="./references#CD001415-bbs2-0015" title="BtaicheIF , WosterPS . Gabapentin and lamotrigine: novel antiepileptic drugs. American Journal of Health-system Pharmacy1995;52(1):61-9. [PMID: 12879525]">Btaiche 1995</a>; <a href="./references#CD001415-bbs2-0021" title="RamsayRE . Clinical efficacy and safety of gabapentin. Neurology1994;44(6 Suppl 5):S23-30;discussion S31-2. [PMID: 8022537]">Ramsay 1994</a>; <a href="./references#CD001415-bbs2-0022" title="SchmidtD , ElgerCE , BrandlU , SchmitzB , SteinhoffBJ , BauerG , et al. Recommendations for the treatment of partial epilepsies with gabapentin A – a consensus. Nervenheilkunde2001;20(10):580-5. ">Schmidt 2001</a>). There were 11 excluded studies overall. </p> <p>The details of these studies are given in the <a href="./references#CD001415-sec-0117" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD001415-sec-0054"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD001415-fig-0002">Figure 2</a> and <a href="#CD001415-fig-0003">Figure 3</a> for a summary of the 'Risk of bias' in each included study. We rated included studies as having low, high or unclear risk of bias for six domains applicable to RCTs: randomisation method, allocation concealment, blinding methods, incomplete outcome data, selective outcome reporting and other sources of bias. </p> <div class="figure" id="CD001415-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001415-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_n/nCD001415-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD001415-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001415-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_n/nCD001415-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD001415-sec-0055"> <h4 class="title">Allocation</h4> <p>Six studies did not describe the method of allocation concealment (authors were contacted but we were unable to clarify) and therefore we rated these at unclear in terms of bias (<a href="./references#CD001415-bbs2-0002" title="AppletonR , FichtnerK , LaMoreauxL , AlexanderJ , HalsallG , MurrayG , et al, and the Gabapentin Paediatric Study Group. Gabapentin as add-on therapy in children with refractory partial seizures: a 12 week, multicentre, double blind placebo controlled study. Epilepsia1999;40(8):1147-54. [PMID: 10448830]">Appleton 1999</a>; <a href="./references#CD001415-bbs2-0005" title="LeachJP , GirvanJ , PaulA , BrodieMJ . Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry1997;62(4):372-6. [PMID: 9120451]">Leach 1997</a>; <a href="./references#CD001415-bbs2-0006" title="LindbergerM , AleniusM , FrisenL , JohannessenSI , LarssonS , MalmgrenK , et al, on behalf of the GREAT Study Investigators Group. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomised, double-blind, dose titration study. Epilepsia2000;41(10):1289-95. [PMID: 11051124]">Lindberger 2000</a>; <a href="./references#CD001415-bbs2-0007" title="SethiA , ChandraD , PuirV , MallikaV . Gabapentin and lamotrigine in Indian patients of partial epilepsy refractory to carbamazepine. Neurology India2002;50(3):359-63. [PMID: 12391470]">Sethi 2002</a>; <a href="./references#CD001415-bbs2-0009" title="TomovicM , IlicT , MihajlovicM , JovicicA . Gabapentin as adjuvant therapy in the treatment of refractory partial epilepsy. Vojnosanitetski Pregled1999;56(2):151-6. [PMID: 10437420]">Tomovic 1999</a>; <a href="./references#CD001415-bbs2-0012" title="YamauchiT , KanekoS , VagiK , SaseS . Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study. Psychiatry and Clinical Neurosciences2006;60(4):507-15. [PMID: 16884455]">Yamauchi 2006</a>). The other six studies achieved randomisation by generating random lists using random permuted blocks and by computer‐generated randomisation; and concealed allocation by dispensing sequentially numbered packages to each participant allocated treatment; we rated these studies at low risk of bias (<a href="./references#CD001415-bbs2-0001" title="AnhutH , AshmanP , FeuersteinTJ , SauermannW , SaundersM , SchmidtB . Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia1994;35(4):795-801. [PMID: 8082624]">Anhut 1994</a>; <a href="./references#CD001415-bbs2-0003" title="FisherRS , SachdeoRC , PellockJ , PenovichPE , MagnusL , BernsteinP . Rapid Initiation of gabapentin: a randomised control trial. Neurology2001;56(6):743-8. [PMID: 11274308]">Fisher 2001</a>; <a href="./references#CD001415-bbs2-0004" title="FrenchJ , GlueP , FriedmanD , AlmasM , YardiN , KnappL , et al. Adjunctive pregabalin vs gabapentin for focal seizures: interpretation of comparative outcomes. Neurology2016;87(12):1242-9. [PMID: 27521437]">French 2016</a>; <a href="./references#CD001415-bbs2-0008" title="SiveniusJ , KalviainenR , YlinenA , RiekkinenP . Double blind study of gabapentin in the treatment of partial seizures. Epilepsia1991;32(4):539-42. [PMID: 1907907]">Sivenius 1991</a>; <a href="./references#CD001415-bbs2-0010" title="UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet1990;335(8698):1114-7. [PMID: 1971862]">UK Gabapentin 1990</a>; <a href="./references#CD001415-bbs2-0011" title="US Gabapentin Study Group No 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology1993;43(11):2292-8. [PMID: 8232945]">US Gabapentin 1993</a>). </p> </section> <section id="CD001415-sec-0056"> <h4 class="title">Blinding</h4> <p>In five studies, the means of blinding was unclear (<a href="./references#CD001415-bbs2-0002" title="AppletonR , FichtnerK , LaMoreauxL , AlexanderJ , HalsallG , MurrayG , et al, and the Gabapentin Paediatric Study Group. Gabapentin as add-on therapy in children with refractory partial seizures: a 12 week, multicentre, double blind placebo controlled study. Epilepsia1999;40(8):1147-54. [PMID: 10448830]">Appleton 1999</a>; <a href="./references#CD001415-bbs2-0004" title="FrenchJ , GlueP , FriedmanD , AlmasM , YardiN , KnappL , et al. Adjunctive pregabalin vs gabapentin for focal seizures: interpretation of comparative outcomes. Neurology2016;87(12):1242-9. [PMID: 27521437]">French 2016</a>; <a href="./references#CD001415-bbs2-0005" title="LeachJP , GirvanJ , PaulA , BrodieMJ . Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry1997;62(4):372-6. [PMID: 9120451]">Leach 1997</a>; <a href="./references#CD001415-bbs2-0007" title="SethiA , ChandraD , PuirV , MallikaV . Gabapentin and lamotrigine in Indian patients of partial epilepsy refractory to carbamazepine. Neurology India2002;50(3):359-63. [PMID: 12391470]">Sethi 2002</a>; <a href="./references#CD001415-bbs2-0009" title="TomovicM , IlicT , MihajlovicM , JovicicA . Gabapentin as adjuvant therapy in the treatment of refractory partial epilepsy. Vojnosanitetski Pregled1999;56(2):151-6. [PMID: 10437420]">Tomovic 1999</a> ); there were no specific details regarding who was blinded (i.e. participants, study personnel or outcome assessors). The remaining seven studies achieved blinding by providing packaging and tablets that were identical in appearance for the gabapentin and placebo groups; and were at low risk of bias for this domain (<a href="./references#CD001415-bbs2-0001" title="AnhutH , AshmanP , FeuersteinTJ , SauermannW , SaundersM , SchmidtB . Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia1994;35(4):795-801. [PMID: 8082624]">Anhut 1994</a>; <a href="./references#CD001415-bbs2-0003" title="FisherRS , SachdeoRC , PellockJ , PenovichPE , MagnusL , BernsteinP . Rapid Initiation of gabapentin: a randomised control trial. Neurology2001;56(6):743-8. [PMID: 11274308]">Fisher 2001</a>; <a href="./references#CD001415-bbs2-0006" title="LindbergerM , AleniusM , FrisenL , JohannessenSI , LarssonS , MalmgrenK , et al, on behalf of the GREAT Study Investigators Group. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomised, double-blind, dose titration study. Epilepsia2000;41(10):1289-95. [PMID: 11051124]">Lindberger 2000</a>; <a href="./references#CD001415-bbs2-0008" title="SiveniusJ , KalviainenR , YlinenA , RiekkinenP . Double blind study of gabapentin in the treatment of partial seizures. Epilepsia1991;32(4):539-42. [PMID: 1907907]">Sivenius 1991</a>; <a href="./references#CD001415-bbs2-0010" title="UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet1990;335(8698):1114-7. [PMID: 1971862]">UK Gabapentin 1990</a>; <a href="./references#CD001415-bbs2-0011" title="US Gabapentin Study Group No 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology1993;43(11):2292-8. [PMID: 8232945]">US Gabapentin 1993</a>; <a href="./references#CD001415-bbs2-0012" title="YamauchiT , KanekoS , VagiK , SaseS . Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study. Psychiatry and Clinical Neurosciences2006;60(4):507-15. [PMID: 16884455]">Yamauchi 2006</a>). </p> </section> <section id="CD001415-sec-0057"> <h4 class="title">Incomplete outcome data</h4> <p>We rated three studies at low risk of bias for attrition bias due to the ITT analyses undertaken by the study authors (<a href="./references#CD001415-bbs2-0002" title="AppletonR , FichtnerK , LaMoreauxL , AlexanderJ , HalsallG , MurrayG , et al, and the Gabapentin Paediatric Study Group. Gabapentin as add-on therapy in children with refractory partial seizures: a 12 week, multicentre, double blind placebo controlled study. Epilepsia1999;40(8):1147-54. [PMID: 10448830]">Appleton 1999</a>; <a href="./references#CD001415-bbs2-0004" title="FrenchJ , GlueP , FriedmanD , AlmasM , YardiN , KnappL , et al. Adjunctive pregabalin vs gabapentin for focal seizures: interpretation of comparative outcomes. Neurology2016;87(12):1242-9. [PMID: 27521437]">French 2016</a>; <a href="./references#CD001415-bbs2-0006" title="LindbergerM , AleniusM , FrisenL , JohannessenSI , LarssonS , MalmgrenK , et al, on behalf of the GREAT Study Investigators Group. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomised, double-blind, dose titration study. Epilepsia2000;41(10):1289-95. [PMID: 11051124]">Lindberger 2000</a>). Seven studies excluded participants from the study and analysis without providing reasons for this; and therefore we rated these at high in terms of bias (<a href="./references#CD001415-bbs2-0001" title="AnhutH , AshmanP , FeuersteinTJ , SauermannW , SaundersM , SchmidtB . Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia1994;35(4):795-801. [PMID: 8082624]">Anhut 1994</a>; <a href="./references#CD001415-bbs2-0003" title="FisherRS , SachdeoRC , PellockJ , PenovichPE , MagnusL , BernsteinP . Rapid Initiation of gabapentin: a randomised control trial. Neurology2001;56(6):743-8. [PMID: 11274308]">Fisher 2001</a>; <a href="./references#CD001415-bbs2-0005" title="LeachJP , GirvanJ , PaulA , BrodieMJ . Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry1997;62(4):372-6. [PMID: 9120451]">Leach 1997</a>; <a href="./references#CD001415-bbs2-0009" title="TomovicM , IlicT , MihajlovicM , JovicicA . Gabapentin as adjuvant therapy in the treatment of refractory partial epilepsy. Vojnosanitetski Pregled1999;56(2):151-6. [PMID: 10437420]">Tomovic 1999</a>; <a href="./references#CD001415-bbs2-0010" title="UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet1990;335(8698):1114-7. [PMID: 1971862]">UK Gabapentin 1990</a>; <a href="./references#CD001415-bbs2-0011" title="US Gabapentin Study Group No 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology1993;43(11):2292-8. [PMID: 8232945]">US Gabapentin 1993</a>; <a href="./references#CD001415-bbs2-0012" title="YamauchiT , KanekoS , VagiK , SaseS . Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study. Psychiatry and Clinical Neurosciences2006;60(4):507-15. [PMID: 16884455]">Yamauchi 2006</a>). Two studies analysed results on an 'as treated' basis, but did report attrition; and were at unclear risk of bias for this domain (<a href="./references#CD001415-bbs2-0007" title="SethiA , ChandraD , PuirV , MallikaV . Gabapentin and lamotrigine in Indian patients of partial epilepsy refractory to carbamazepine. Neurology India2002;50(3):359-63. [PMID: 12391470]">Sethi 2002</a>; <a href="./references#CD001415-bbs2-0008" title="SiveniusJ , KalviainenR , YlinenA , RiekkinenP . Double blind study of gabapentin in the treatment of partial seizures. Epilepsia1991;32(4):539-42. [PMID: 1907907]">Sivenius 1991</a>). </p> </section> <section id="CD001415-sec-0058"> <h4 class="title">Selective reporting</h4> <p>We rated all included studies at low risk of reporting bias as there was no suspicion of selective outcome reporting bias: all expected outcomes were reported in each of the publications. </p> </section> <section id="CD001415-sec-0059"> <h4 class="title">Other potential sources of bias</h4> <p>Parke Davis, the manufacturers of gabapentin, sponsored nine trials (<a href="./references#CD001415-bbs2-0001" title="AnhutH , AshmanP , FeuersteinTJ , SauermannW , SaundersM , SchmidtB . Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia1994;35(4):795-801. [PMID: 8082624]">Anhut 1994</a>; <a href="./references#CD001415-bbs2-0002" title="AppletonR , FichtnerK , LaMoreauxL , AlexanderJ , HalsallG , MurrayG , et al, and the Gabapentin Paediatric Study Group. Gabapentin as add-on therapy in children with refractory partial seizures: a 12 week, multicentre, double blind placebo controlled study. Epilepsia1999;40(8):1147-54. [PMID: 10448830]">Appleton 1999</a>; <a href="./references#CD001415-bbs2-0003" title="FisherRS , SachdeoRC , PellockJ , PenovichPE , MagnusL , BernsteinP . Rapid Initiation of gabapentin: a randomised control trial. Neurology2001;56(6):743-8. [PMID: 11274308]">Fisher 2001</a>; <a href="./references#CD001415-bbs2-0005" title="LeachJP , GirvanJ , PaulA , BrodieMJ . Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry1997;62(4):372-6. [PMID: 9120451]">Leach 1997</a>; <a href="./references#CD001415-bbs2-0006" title="LindbergerM , AleniusM , FrisenL , JohannessenSI , LarssonS , MalmgrenK , et al, on behalf of the GREAT Study Investigators Group. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomised, double-blind, dose titration study. Epilepsia2000;41(10):1289-95. [PMID: 11051124]">Lindberger 2000</a>; <a href="./references#CD001415-bbs2-0008" title="SiveniusJ , KalviainenR , YlinenA , RiekkinenP . Double blind study of gabapentin in the treatment of partial seizures. Epilepsia1991;32(4):539-42. [PMID: 1907907]">Sivenius 1991</a>; <a href="./references#CD001415-bbs2-0010" title="UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet1990;335(8698):1114-7. [PMID: 1971862]">UK Gabapentin 1990</a>; <a href="./references#CD001415-bbs2-0011" title="US Gabapentin Study Group No 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology1993;43(11):2292-8. [PMID: 8232945]">US Gabapentin 1993</a>; <a href="./references#CD001415-bbs2-0012" title="YamauchiT , KanekoS , VagiK , SaseS . Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study. Psychiatry and Clinical Neurosciences2006;60(4):507-15. [PMID: 16884455]">Yamauchi 2006</a>). Pfizer Inc., the manufacturer of gabapentin and pregabalin, funded one trial (<a href="./references#CD001415-bbs2-0004" title="FrenchJ , GlueP , FriedmanD , AlmasM , YardiN , KnappL , et al. Adjunctive pregabalin vs gabapentin for focal seizures: interpretation of comparative outcomes. Neurology2016;87(12):1242-9. [PMID: 27521437]">French 2016</a>). Therefore, we rated these 10 trials at high risk of funding bias. <a href="http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD001415.pub2/full#CD001415-bbs2-0006" target="_blank">Sethi 2002</a> and <a href="http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD001415.pub2/full#CD001415-bbs2-0008" target="_blank">Tomovic 1999</a> were at low risk for this domain. There was no evidence of further bias in any of the included studies. </p> </section> </section> <section id="CD001415-sec-0060"> <h3 class="title" id="CD001415-sec-0060">Effects of interventions</h3> <p>See: <a href="./full#CD001415-tbl-0001"><b>Summary of findings 1</b> Gabapentin versus placebo for people with drug‐resistant focal epilepsy</a> </p> <section id="CD001415-sec-0061"> <h4 class="title">Gabapentin versus placebo</h4> <p>Seven trials compared gabapentin to placebo (<a href="./references#CD001415-bbs2-0001" title="AnhutH , AshmanP , FeuersteinTJ , SauermannW , SaundersM , SchmidtB . Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia1994;35(4):795-801. [PMID: 8082624]">Anhut 1994</a>; <a href="./references#CD001415-bbs2-0002" title="AppletonR , FichtnerK , LaMoreauxL , AlexanderJ , HalsallG , MurrayG , et al, and the Gabapentin Paediatric Study Group. Gabapentin as add-on therapy in children with refractory partial seizures: a 12 week, multicentre, double blind placebo controlled study. Epilepsia1999;40(8):1147-54. [PMID: 10448830]">Appleton 1999</a>; <a href="./references#CD001415-bbs2-0005" title="LeachJP , GirvanJ , PaulA , BrodieMJ . Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry1997;62(4):372-6. [PMID: 9120451]">Leach 1997</a>; <a href="./references#CD001415-bbs2-0008" title="SiveniusJ , KalviainenR , YlinenA , RiekkinenP . Double blind study of gabapentin in the treatment of partial seizures. Epilepsia1991;32(4):539-42. [PMID: 1907907]">Sivenius 1991</a>; <a href="./references#CD001415-bbs2-0010" title="UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet1990;335(8698):1114-7. [PMID: 1971862]">UK Gabapentin 1990</a>; <a href="./references#CD001415-bbs2-0011" title="US Gabapentin Study Group No 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology1993;43(11):2292-8. [PMID: 8232945]">US Gabapentin 1993</a>; <a href="./references#CD001415-bbs2-0012" title="YamauchiT , KanekoS , VagiK , SaseS . Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study. Psychiatry and Clinical Neurosciences2006;60(4):507-15. [PMID: 16884455]">Yamauchi 2006</a>). </p> <section id="CD001415-sec-0062"> <h5 class="title">Reduction in seizure frequency of 50% or more</h5> <p>Given that all participants had drug‐resistant focal epilepsy, it seemed reasonable to combine results from the paediatric and adult studies for an overall estimate (irrespective of dose). Data from the paediatric study could not be included in dose regression models, as participants were not randomised to a specific daily dose (<a href="./references#CD001415-bbs2-0002" title="AppletonR , FichtnerK , LaMoreauxL , AlexanderJ , HalsallG , MurrayG , et al, and the Gabapentin Paediatric Study Group. Gabapentin as add-on therapy in children with refractory partial seizures: a 12 week, multicentre, double blind placebo controlled study. Epilepsia1999;40(8):1147-54. [PMID: 10448830]">Appleton 1999</a>). Seven trials provided data for this outcome (<a href="./references#CD001415-bbs2-0001" title="AnhutH , AshmanP , FeuersteinTJ , SauermannW , SaundersM , SchmidtB . Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia1994;35(4):795-801. [PMID: 8082624]">Anhut 1994</a>; <a href="./references#CD001415-bbs2-0002" title="AppletonR , FichtnerK , LaMoreauxL , AlexanderJ , HalsallG , MurrayG , et al, and the Gabapentin Paediatric Study Group. Gabapentin as add-on therapy in children with refractory partial seizures: a 12 week, multicentre, double blind placebo controlled study. Epilepsia1999;40(8):1147-54. [PMID: 10448830]">Appleton 1999</a>; <a href="./references#CD001415-bbs2-0005" title="LeachJP , GirvanJ , PaulA , BrodieMJ . Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry1997;62(4):372-6. [PMID: 9120451]">Leach 1997</a>; <a href="./references#CD001415-bbs2-0008" title="SiveniusJ , KalviainenR , YlinenA , RiekkinenP . Double blind study of gabapentin in the treatment of partial seizures. Epilepsia1991;32(4):539-42. [PMID: 1907907]">Sivenius 1991</a>; <a href="./references#CD001415-bbs2-0010" title="UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet1990;335(8698):1114-7. [PMID: 1971862]">UK Gabapentin 1990</a>; <a href="./references#CD001415-bbs2-0011" title="US Gabapentin Study Group No 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology1993;43(11):2292-8. [PMID: 8232945]">US Gabapentin 1993</a>; <a href="./references#CD001415-bbs2-0012" title="YamauchiT , KanekoS , VagiK , SaseS . Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study. Psychiatry and Clinical Neurosciences2006;60(4):507-15. [PMID: 16884455]">Yamauchi 2006</a>). See <a href="#CD001415-fig-0004">Figure 4</a> for forest plots. One trial was not suitable for inclusion in the meta‐analysis due to the cross‐over design but was discussed in narrative form below (<a href="./references#CD001415-bbs2-0005" title="LeachJP , GirvanJ , PaulA , BrodieMJ . Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry1997;62(4):372-6. [PMID: 9120451]">Leach 1997</a>). </p> <div class="figure" id="CD001415-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Gabapentin versus placebo, outcome: 1.1 Reduction in seizure frequency 50% or greater." data-id="CD001415-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_n/nCD001415-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Gabapentin versus placebo, outcome: 1.1 Reduction in seizure frequency 50% or greater. </p> </div> </div> </div> <section id="CD001415-sec-0063"> <h6 class="title">Intention‐to‐treat analysis</h6> <p>An analysis pooling data from six studies showed no evidence of heterogeneity (Chi<sup>2</sup> = 3.90, P = 0.56, I<sup>2</sup> = 0%). The overall RR for reduction in seizure frequency of 50% or more was 1.89 (95% CI 1.40 to 2.55; 1206 participants; moderate‐certainty evidence; <a href="./references#CD001415-fig-0005" title="">Analysis 1.1</a>). </p> <section id="CD001415-sec-0064"> <p><b>Best‐case and worst‐case scenarios</b></p> <p>Chi<sup>2</sup> tests for heterogeneity for a response to gabapentin indicated no significant heterogeneity (best‐case: P = 0.08; worst‐case: P = 0.95). The overall RRs for 50% responders across all studies were 2.52 (95% CI 1.89 to 3.37) for best‐case scenarios and 1.35 (95% CI 1.04 to 1.76) for worst‐case scenarios (<a href="./references#CD001415-fig-0005" title="">Analysis 1.1</a>). </p> <p>For all three analyses, the results suggested a significant treatment effect. However, there was a considerable difference between estimates. </p> </section> </section> <section id="CD001415-sec-0065"> <h6 class="title">Dose‐response regression</h6> <section id="CD001415-sec-0066"> <p><b>Intention‐to‐treat analysis</b></p> <p>A linear dose‐response model gave a good summary (for the five adult trials) of the log odds of 50% response rate. After adjusting for dose, there was no difference in estimated dose‐response between studies. The log odds of response increase by 0.19 (standard error of the mean (SEM) 0.045) for a 300 mg increase in daily gabapentin dose. This is about a 20% increase in the odds of response with a 300 mg increase in gabapentin dose. The reduction in deviance due to dose was 19.1 on one degree of freedom, and the residual deviance was 10.9 on 13 degrees of freedom. The trial in children was not included, as the doses were prescribed to achieve particular levels of milligrams per kilogram per day. </p> <p>The results were summarised in <a href="#CD001415-tbl-0002">Table 1</a>; <a href="#CD001415-tbl-0003">Table 2</a>; <a href="#CD001415-tbl-0004">Table 3</a>: </p> <div class="table" id="CD001415-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Estimated percentage responders and percentage difference compared to placebo per gabapentin dose, intention‐to‐treat</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% Responders (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% Difference (95% CI) compared to placebo</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 mg (placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7 (7.2 to 12.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6 (11.4 to 16.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9 (1.6 to 6.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>900 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.0 (13.7 to 18.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.3 (2.8 to 9.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.7 (15.8 to 22.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.0 (4.4 to 13.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1800 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.3 (19.3 to 32.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.5 (8.5 to 22.5)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval.</p> </div> </div> <div class="table" id="CD001415-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Estimated percentage responders and percentage difference compared to placebo per gabapentin dose, best‐case</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Responders % (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% Difference (95% CI) compared to placebo</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 mg (placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.9 (8.1 to 14.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.2 (14.6 to 20.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.3 (3.9 to 8.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>900 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.4 (18.5 to 24.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.5 (6.8 to 14.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.2 (22.4 to 30.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.3 (10.3 to 20.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1800 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.6 (30.0 to 46.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.7 (19.3 to 34.2)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval.</p> </div> </div> <div class="table" id="CD001415-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Estimated percentage responders and percentage difference compared to placebo per gabapentin dose, worst‐case</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Responders % (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% Difference (95% CI) compared to placebo</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 mg (placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.8 (10.4 to 18.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.4 (13.8 to 19.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 (–0.3 to 5.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>900 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.8 (15.3 to 20.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9 (–0.3 to 8.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.2 (16.2 to 22.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.4 (–0.2 to 11.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1800 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.5 (17.1 to 29.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.6 (0.3 to 17.0)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval.</p> </div> </div> <p> <ul id="CD001415-list-0013"> <li> <p>the estimated percentage of participants responding to each gabapentin dose and the percentage difference in participants responding to each gabapentin dose compared to placebo with 95% CI (ITT) (<a href="#CD001415-tbl-0002">Table 1</a>); </p> </li> <li> <p>the estimated percentage of participants responding to each gabapentin dose and the percentage difference in participants responding to each gabapentin dose compared to placebo with 95% CI (best‐case) (<a href="#CD001415-tbl-0003">Table 2</a>); </p> </li> <li> <p>the estimated percentage of participants responding to each gabapentin dose and the percentage difference in participants responding to each gabapentin dose compared to placebo with 95% CI (worst‐case) (<a href="#CD001415-tbl-0004">Table 3</a>). </p> </li> </ul> </p> <p>In the best‐case analysis, there was about a 30% increase in the odds of response with a 300 mg increase in gabapentin dose and in the worst‐case analysis, there was about a 10% increase in the odds of response with a 300 mg increase in gabapentin dose. </p> <p>All three analyses (ITT, best‐case and worst‐case) showed a significant increase in therapeutic effect with increasing dose. However, there was a striking difference in the proportion of responders estimated. </p> </section> </section> </section> <section id="CD001415-sec-0067"> <h5 class="title">Seizure freedom</h5> <p>Only two trials comparing gabapentin to placebo reported seizure freedom data (<a href="./references#CD001415-bbs2-0002" title="AppletonR , FichtnerK , LaMoreauxL , AlexanderJ , HalsallG , MurrayG , et al, and the Gabapentin Paediatric Study Group. Gabapentin as add-on therapy in children with refractory partial seizures: a 12 week, multicentre, double blind placebo controlled study. Epilepsia1999;40(8):1147-54. [PMID: 10448830]">Appleton 1999</a>; <a href="./references#CD001415-bbs2-0012" title="YamauchiT , KanekoS , VagiK , SaseS . Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study. Psychiatry and Clinical Neurosciences2006;60(4):507-15. [PMID: 16884455]">Yamauchi 2006</a>). </p> <p><a href="./references#CD001415-bbs2-0012" title="YamauchiT , KanekoS , VagiK , SaseS . Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study. Psychiatry and Clinical Neurosciences2006;60(4):507-15. [PMID: 16884455]">Yamauchi 2006</a> reported no participants attaining seizure freedom, whereas <a href="./references#CD001415-bbs2-0002" title="AppletonR , FichtnerK , LaMoreauxL , AlexanderJ , HalsallG , MurrayG , et al, and the Gabapentin Paediatric Study Group. Gabapentin as add-on therapy in children with refractory partial seizures: a 12 week, multicentre, double blind placebo controlled study. Epilepsia1999;40(8):1147-54. [PMID: 10448830]">Appleton 1999</a> reported 3/119 participants receiving gabapentin as seizure‐free compared to 1/128 participants receiving placebo. Due to the very small numbers of participants achieving seizure freedom in the two trials, the data were not combined in meta‐analyses. </p> </section> <section id="CD001415-sec-0068"> <h5 class="title">Treatment withdrawal</h5> <p>A Chi<sup>2</sup> test of heterogeneity suggested no significant statistical heterogeneity (Chi<sup>2</sup> = 4.13, df = 4, P = 0.53, I<sup>2</sup> = 0%). The overall RR for withdrawal for any reason was 1.05 (95% CI 0.74 to 1.49; 6 trials, 1206 participants; moderate‐certainty evidence; <a href="./references#CD001415-fig-0006" title="">Analysis 1.2</a>), hence there was insufficient evidence to conclude that people were more likely to withdraw from gabapentin than placebo, but there could have been a substantial withdrawal rate. </p> </section> <section id="CD001415-sec-0069"> <h5 class="title">Adverse effects</h5> <p>In addition to reports of ataxia, dizziness, fatigue, nausea and somnolence, headache was among the six most common adverse effects included in our analysis. There were significant differences between gabapentin and placebo for the following adverse effects (see <a href="./references#CD001415-fig-0007" title="">Analysis 1.3</a>): ataxia (RR 2.01, 99% CI 0.98 to 4.11; 3 RCTs; 787 participants; low‐certainty evidence); dizziness (RR 2.43, 99% CI 1.44 to 4.12; 6 RCTs; 1206 participants; moderate‐certainty evidence); fatigue (RR 1.95, 99% CI 0.99 to 3.82; 5 RCTs; 1161 participants; low‐certainty evidence) and somnolence (RR 1.93, 99% CI 1.22 to 3.06; 6 RCTs, 1206 participants; moderate‐certainty evidence). There was no evidence of a difference for headache (RR 0.79, 99% CI 0.46 to 1.35; 6 RCTs, 1206 participants; moderate‐certainty evidence) or nausea (RR 0.95, 99% CI 0.52 to 1.73; 4 RCTs, 1034 participants; moderate‐certainty evidence). </p> </section> <section id="CD001415-sec-0070"> <h5 class="title">Cross‐over trial, not included in meta‐analysis</h5> <p>One trial was not suitable for inclusion in the meta‐analysis due to the cross‐over design and due to a lack of a prerandomisation baseline period and was discussed in narrative form (<a href="./references#CD001415-bbs2-0005" title="LeachJP , GirvanJ , PaulA , BrodieMJ . Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry1997;62(4):372-6. [PMID: 9120451]">Leach 1997</a>). </p> <section id="CD001415-sec-0071"> <h6 class="title">Reduction in seizure frequency of 50% or more and seizure freedom</h6> <p>The cross‐over trial evaluated 23/27 participants (although there were six withdrawals, two participants withdrew sufficiently late in the study to provide analysable data). Two participants achieved total seizure control throughout the active treatment phase and none in the placebo phase. For simple focal seizures, two participants showed 'in excess' of 50% reduction in seizure frequency. The median monthly frequency for simple focal seizures was not significantly reduced in the treatment group (P = 0.80). The study reported complex focal seizures with secondary generalisation separately; 5/17 participants had in excess of 50% reduction in seizure frequency (non‐significant). </p> </section> <section id="CD001415-sec-0072"> <h6 class="title">Treatment withdrawal</h6> <p>Six participants withdrew, five due to adverse effects (four while receiving placebo, one while receiving gabapentin) and one of whom withdrew consent to participate after the second visit. One participant did not provide complete data for seizure frequency and was withdrawn from the study. </p> </section> <section id="CD001415-sec-0073"> <h6 class="title">Adverse effects</h6> <p>Nineteen (79%) participants reported 47 adverse effects with gabapentin and 15 participants (63%) reported 30 adverse effects with placebo. There was a statistically significant difference (P = 0.006) with gabapentin 2400 mg/day. The types of adverse effects were not reported. </p> </section> </section> </section> <section id="CD001415-sec-0074"> <h4 class="title">Dose comparison trials with no placebo group</h4> <p>Two studies compared two dose regimens with no placebo (<a href="./references#CD001415-bbs2-0003" title="FisherRS , SachdeoRC , PellockJ , PenovichPE , MagnusL , BernsteinP . Rapid Initiation of gabapentin: a randomised control trial. Neurology2001;56(6):743-8. [PMID: 11274308]">Fisher 2001</a>; <a href="./references#CD001415-bbs2-0009" title="TomovicM , IlicT , MihajlovicM , JovicicA . Gabapentin as adjuvant therapy in the treatment of refractory partial epilepsy. Vojnosanitetski Pregled1999;56(2):151-6. [PMID: 10437420]">Tomovic 1999</a>). For one study, we sent a data extraction form to a translator (<a href="./references#CD001415-bbs2-0009" title="TomovicM , IlicT , MihajlovicM , JovicicA . Gabapentin as adjuvant therapy in the treatment of refractory partial epilepsy. Vojnosanitetski Pregled1999;56(2):151-6. [PMID: 10437420]">Tomovic 1999</a>). Our understanding is that the study combined outcomes for the two treatment arms, thus a comparison between the two treatment groups could not be made. Another study only measured adverse effects at day two and day seven of a slow initiation regimen and a rapid initiation regimen; therefore, this is presented narratively below (<a href="./references#CD001415-bbs2-0003" title="FisherRS , SachdeoRC , PellockJ , PenovichPE , MagnusL , BernsteinP . Rapid Initiation of gabapentin: a randomised control trial. Neurology2001;56(6):743-8. [PMID: 11274308]">Fisher 2001</a>). </p> <section id="CD001415-sec-0075"> <h5 class="title">Reduction in seizure frequency of 50% or more</h5> <p>In the <a href="./references#CD001415-bbs2-0009" title="TomovicM , IlicT , MihajlovicM , JovicicA . Gabapentin as adjuvant therapy in the treatment of refractory partial epilepsy. Vojnosanitetski Pregled1999;56(2):151-6. [PMID: 10437420]">Tomovic 1999</a> study, 13/18 (72.2%) participants experienced 50% or greater reduction in seizures (two of whom achieved a 100% reduction). Three participants had a 26% to 49% reduction in seizure frequency. Two participants had worse seizure control. <a href="./references#CD001415-bbs2-0003" title="FisherRS , SachdeoRC , PellockJ , PenovichPE , MagnusL , BernsteinP . Rapid Initiation of gabapentin: a randomised control trial. Neurology2001;56(6):743-8. [PMID: 11274308]">Fisher 2001</a> did not measure reduction in seizure frequency of 50% or more. </p> </section> <section id="CD001415-sec-0076"> <h5 class="title">Seizure freedom</h5> <p>In the <a href="./references#CD001415-bbs2-0009" title="TomovicM , IlicT , MihajlovicM , JovicicA . Gabapentin as adjuvant therapy in the treatment of refractory partial epilepsy. Vojnosanitetski Pregled1999;56(2):151-6. [PMID: 10437420]">Tomovic 1999</a> study, 2/18 (11.1%) participants were seizure‐free during the treatment period; however, it was not reported in which dose group this was achieved. <a href="./references#CD001415-bbs2-0003" title="FisherRS , SachdeoRC , PellockJ , PenovichPE , MagnusL , BernsteinP . Rapid Initiation of gabapentin: a randomised control trial. Neurology2001;56(6):743-8. [PMID: 11274308]">Fisher 2001</a> did not measure seizure freedom. </p> </section> <section id="CD001415-sec-0077"> <h5 class="title">Treatment withdrawals</h5> <p><a href="./references#CD001415-bbs2-0009" title="TomovicM , IlicT , MihajlovicM , JovicicA . Gabapentin as adjuvant therapy in the treatment of refractory partial epilepsy. Vojnosanitetski Pregled1999;56(2):151-6. [PMID: 10437420]">Tomovic 1999</a> did not report any treatment withdrawals. <a href="./references#CD001415-bbs2-0003" title="FisherRS , SachdeoRC , PellockJ , PenovichPE , MagnusL , BernsteinP . Rapid Initiation of gabapentin: a randomised control trial. Neurology2001;56(6):743-8. [PMID: 11274308]">Fisher 2001</a> reported only participants who had full exposure to the study medication during the whole period of assessment (i.e. details of withdrawals were not provided). </p> </section> <section id="CD001415-sec-0078"> <h5 class="title">Adverse effects</h5> <p><a href="./references#CD001415-bbs2-0009" title="TomovicM , IlicT , MihajlovicM , JovicicA . Gabapentin as adjuvant therapy in the treatment of refractory partial epilepsy. Vojnosanitetski Pregled1999;56(2):151-6. [PMID: 10437420]">Tomovic 1999</a> reported adverse effects in three participants, two of whom had dizziness and one had excessive sleepiness (they were excluded from the study, therefore, not included in the total number of participants). They also noted bulimia, tremor, diplopia, headache, nausea and ataxia. <a href="./references#CD001415-bbs2-0003" title="FisherRS , SachdeoRC , PellockJ , PenovichPE , MagnusL , BernsteinP . Rapid Initiation of gabapentin: a randomised control trial. Neurology2001;56(6):743-8. [PMID: 11274308]">Fisher 2001</a> reported adverse effects on day three and day seven of a slow and rapid initiation regimen of gabapentin. See <a href="#CD001415-tbl-0005">Table 4</a> for the proportion of people with adverse effects with percentages. There were no statistically significant differences between the two dose regimens, apart from more dizziness in the rapid initiation group compared to the slow initiation group at day three only. In addition, <a href="./references#CD001415-bbs2-0009" title="TomovicM , IlicT , MihajlovicM , JovicicA . Gabapentin as adjuvant therapy in the treatment of refractory partial epilepsy. Vojnosanitetski Pregled1999;56(2):151-6. [PMID: 10437420]">Tomovic 1999</a> reported 24‐hour electroencephalogram (EEG) recordings pre‐ and postintervention and revealed a reduction in total epileptiform discharges from 229.87 to 167.13. </p> <div class="table" id="CD001415-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse effects Fisher 2001</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse effect</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Slow initiation (day 2)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rapid initiation (day 2)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Slow initiation (day 7)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rapid initiation (day 7)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>%</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Fatigue</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/280</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/294</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/274</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/294</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dizziness</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/280</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/294</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45/276</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59/293</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.1</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Somnolence</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/280</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/294</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/275</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/293</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.6</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ataxia</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/280</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/294</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/275</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/294</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1</p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD001415-sec-0079"> <h4 class="title">Gabapentin versus vigabatrin</h4> <p>One study compared gabapentin versus vigabatrin (<a href="./references#CD001415-bbs2-0006" title="LindbergerM , AleniusM , FrisenL , JohannessenSI , LarssonS , MalmgrenK , et al, on behalf of the GREAT Study Investigators Group. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomised, double-blind, dose titration study. Epilepsia2000;41(10):1289-95. [PMID: 11051124]">Lindberger 2000</a>). </p> <section id="CD001415-sec-0080"> <h5 class="title">Reduction in seizure frequency of 50% or more and seizure freedom</h5> <p>The study noted a reduction in seizure frequency of 50% or more and seizure freedom in 27/50 (54%) participants in the gabapentin group and 34/52 (56%) participants in the vigabatrin group (on an ITT basis); the 95% CIs were wide and this was not deemed statistically significant. The proportion seizure‐free without adverse effects was 13/50 (26%) participants in the gabapentin group and 18/52 (35%) participants in the vigabatrin group. This was not statistically significant. The study measured an extra variable of 'improvement rate' (proportion of participants with 50% or greater seizure reduction without adverse effects), which was 24/50 (48%) participants in the gabapentin group and 29/52 (56%) participants in the vigabatrin group. Thirteen out of 50 participants were seizure‐free in the gabapentin group compared to 18/52 participants in the vigabatrin group. </p> </section> <section id="CD001415-sec-0081"> <h5 class="title">Treatment withdrawals</h5> <p>There were 14 withdrawals from the study as a result of adverse effects, seven in each group. In the gabapentin group, they were status epilepticus, psychiatric problems, epigastric pain, diplopia, vertigo and dizziness (three participants); in the vigabatrin group, they were depression, generalised seizure, rash, numbness and dizziness (three participants). </p> </section> <section id="CD001415-sec-0082"> <h5 class="title">Adverse effects</h5> <p>In the gabapentin group, three participants experienced serious adverse effects which were status epilepticus, pyelonephritis and psychiatric problems. In the vigabatrin group, four participants had serious adverse effects, which were agitation, depression, weight gain, mononucleosis and a secondary generalised seizure. Thirty‐eight (76%) participants in the gabapentin group and 45 (86.5%) participants in the vigabatrin group experienced adverse effects of any type. The five most common adverse effects were similar in both groups (tiredness, dizziness, respiratory infection, headache and diarrhoea). Specific proportions of individual adverse effects were not provided. </p> </section> </section> <section id="CD001415-sec-0083"> <h4 class="title">Gabapentin versus lamotrigine</h4> <p>One trial compared gabapentin versus lamotrigine (<a href="./references#CD001415-bbs2-0007" title="SethiA , ChandraD , PuirV , MallikaV . Gabapentin and lamotrigine in Indian patients of partial epilepsy refractory to carbamazepine. Neurology India2002;50(3):359-63. [PMID: 12391470]">Sethi 2002</a>). </p> <section id="CD001415-sec-0084"> <h5 class="title">Reduction in seizure frequency of 50% or more and seizure freedom</h5> <p>There was a 50% or greater reduction in seizure frequency by 77.7% of participants in the gabapentin group and 92% of participants in the lamotrigine group (ITT analysis). There was complete seizure control in 8/27 (29.6%) participants in the gabapentin group; this was not specified in the lamotrigine group. </p> </section> <section id="CD001415-sec-0085"> <h5 class="title">Treatment withdrawals</h5> <p><a href="./references#CD001415-bbs2-0007" title="SethiA , ChandraD , PuirV , MallikaV . Gabapentin and lamotrigine in Indian patients of partial epilepsy refractory to carbamazepine. Neurology India2002;50(3):359-63. [PMID: 12391470]">Sethi 2002</a> did not report any treatment withdrawals. </p> </section> <section id="CD001415-sec-0086"> <h5 class="title">Adverse effects</h5> <p>Twenty‐two out of 27 (81.5%) participants in the gabapentin group and 18/25 (72%) participants in the lamotrigine group reported adverse effects. The most common adverse effects were neurotoxic: dizziness (gabapentin: 22.2%; lamotrigine: 28%), diplopia (gabapentin: 11.11%; lamotrigine: 24%), weakness (gabapentin: 14.8%; lamotrigine: 24%), headache (gabapentin: 25.9%; lamotrigine: 20%), drowsiness (gabapentin: 14.8%; lamotrigine: 12%), tiredness (gabapentin: 14.8%; lamotrigine: 4%), amnesia (gabapentin: 11.11%; lamotrigine: 12%), tingling sensation (gabapentin: 11.11%; lamotrigine: 0%) and anorexia (gabapentin: 11.11%; lamotrigine: 8%). </p> <p>There were no serious adverse effects in the gabapentin group. In the lamotrigine group, there were two serious adverse effects: Steven‐Johnson's syndrome and anxiety neurosis (corresponding with an increase in seizure frequency). There was an increase in the number of seizures in one participant receiving gabapentin 2400 mg/day. In the gabapentin group, there was a change of seizure type from focal seizures to myoclonic jerks or atypical seizures in five participants during treatment. In the lamotrigine group, seizure type changed to atypical absence (two participants) and pseudoseizures (two participants). </p> <p>Additionally, the benefit of gabapentin was more pronounced in participants with simple focal seizures with secondary generalisation than in participants with simple and complex focal seizures without secondary generalisation, whereas all subtypes of epilepsy responded similarly in the lamotrigine group. </p> </section> </section> <section id="CD001415-sec-0087"> <h4 class="title">Gabapentin versus pregabalin</h4> <p>One study compared gabapentin versus pregabalin (<a href="./references#CD001415-bbs2-0004" title="FrenchJ , GlueP , FriedmanD , AlmasM , YardiN , KnappL , et al. Adjunctive pregabalin vs gabapentin for focal seizures: interpretation of comparative outcomes. Neurology2016;87(12):1242-9. [PMID: 27521437]">French 2016</a>). </p> <section id="CD001415-sec-0088"> <h5 class="title">Reduction in seizure frequency of 50% or more and seizure freedom</h5> <p>There was a reduction in seizure frequency of 50% or more in 140/240 (58.3%) participants in the gabapentin group and 134/238 (56.3%) participants in the pregabalin groups (on an ITT basis); the 95% CIs were wide and this was not deemed statistically significant. The proportion of seizure‐free participants was 62/182 (34.1%) in the gabapentin group and 58/189 (30.7%) in the pregabalin group; these were not statistically significant. The study measured an extra variable of 'improvement rate' (proportion of participants with 75% or greater seizure reduction) and was 82/240 (34.2%) participants in the gabapentin group and 80/238 (33.6%) participants in the pregabalin group. </p> </section> <section id="CD001415-sec-0089"> <h5 class="title">Treatment withdrawals</h5> <p>There were 123 withdrawals for any reason from the study, and 31 due to adverse effects (16 in the gabapentin group and 15 in the pregabalin group). In the gabapentin group, the adverse effects were status epilepticus, psychiatric problems, epigastric pain, diplopia, vertigo and dizziness (three participants); in the vigabatrin group, they were depression, generalised seizure, rash, numbness and dizziness (three participants). </p> </section> <section id="CD001415-sec-0090"> <h5 class="title">Adverse effects</h5> <p>In the gabapentin group, 129/241 (53.5%) participants reported adverse effects and, in the pregabalin group, 142/241 (58.9%) participants reported adverse effects. Both groups had six (2.5%) participants with serious adverse effects. The five most common adverse effects were similar in both groups (somnolence, dizziness, headache, increased weight and dry mouth). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001415-sec-0091" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001415-sec-0091"></div> <section id="CD001415-sec-0092"> <h3 class="title" id="CD001415-sec-0092">Summary of main results</h3> <p>The results of the overall efficacy analysis showed that gabapentin reduced seizure frequency when used as an add‐on AED in people with drug‐resistant focal epilepsy. Compared to placebo, gabapentin was almost twice as likely to reduce seizures by 50% or more; however, there was considerable discrepancy between the results of the ITT and best‐case and worst‐case analyses, hence the ITT analyses need to be interpreted with caution (see <a href="#CD001415-sec-0099">Implications for research</a>). The dose‐response regression analysis indicated increasing efficacy with increasing dose. Results suggested that the therapeutic effect of gabapentin 600 mg/day, although statistically significant, was small and 900 mg/day would seem a better initial dose. In addition, there was no apparent 'plateau' of therapeutic effects at the doses tested and it may well be that optimal doses of gabapentin have not been tested. </p> <p>This was also reflected to a much greater extent by the studies described in narrative form. The <a href="./references#CD001415-bbs2-0009" title="TomovicM , IlicT , MihajlovicM , JovicicA . Gabapentin as adjuvant therapy in the treatment of refractory partial epilepsy. Vojnosanitetski Pregled1999;56(2):151-6. [PMID: 10437420]">Tomovic 1999</a> study comparing gabapentin doses reported 72.2% of the 18 participants evaluated as having a 50% or greater reduction in seizure frequency outcome (compared to 16% to 22% taken from the studies comparing gabapentin to placebo combined in meta‐analysis) even though the demographics and treatment doses were comparable. Similarly, the active control trials reported a 54% response rate in <a href="./references#CD001415-bbs2-0006" title="LindbergerM , AleniusM , FrisenL , JohannessenSI , LarssonS , MalmgrenK , et al, on behalf of the GREAT Study Investigators Group. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomised, double-blind, dose titration study. Epilepsia2000;41(10):1289-95. [PMID: 11051124]">Lindberger 2000</a> (compared to vigabatrin), 58% response rate in <a href="./references#CD001415-bbs2-0004" title="FrenchJ , GlueP , FriedmanD , AlmasM , YardiN , KnappL , et al. Adjunctive pregabalin vs gabapentin for focal seizures: interpretation of comparative outcomes. Neurology2016;87(12):1242-9. [PMID: 27521437]">French 2016</a> (compared to pregabalin) and 77% response rate in <a href="./references#CD001415-bbs2-0007" title="SethiA , ChandraD , PuirV , MallikaV . Gabapentin and lamotrigine in Indian patients of partial epilepsy refractory to carbamazepine. Neurology India2002;50(3):359-63. [PMID: 12391470]">Sethi 2002</a> (compared to lamotrigine). This could potentially be due to two key differences in methodology: the definition of 'drug‐resistant' focal epilepsy and to the dosing regimens. <a href="./references#CD001415-bbs2-0006" title="LindbergerM , AleniusM , FrisenL , JohannessenSI , LarssonS , MalmgrenK , et al, on behalf of the GREAT Study Investigators Group. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomised, double-blind, dose titration study. Epilepsia2000;41(10):1289-95. [PMID: 11051124]">Lindberger 2000</a> defined drug resistance as failure to respond to no more than two AED monotherapy regimens and gabapentin was always added to monotherapy. <a href="./references#CD001415-bbs2-0007" title="SethiA , ChandraD , PuirV , MallikaV . Gabapentin and lamotrigine in Indian patients of partial epilepsy refractory to carbamazepine. Neurology India2002;50(3):359-63. [PMID: 12391470]">Sethi 2002</a> only recruited people resistant to carbamazepine monotherapy and 88% of participants in the <a href="./references#CD001415-bbs2-0009" title="TomovicM , IlicT , MihajlovicM , JovicicA . Gabapentin as adjuvant therapy in the treatment of refractory partial epilepsy. Vojnosanitetski Pregled1999;56(2):151-6. [PMID: 10437420]">Tomovic 1999</a> study were taking one other AED only. As the remaining studies used people with drug‐resistant focal seizures who were established on one or two AEDs and stable doses (apart from <a href="./references#CD001415-bbs2-0002" title="AppletonR , FichtnerK , LaMoreauxL , AlexanderJ , HalsallG , MurrayG , et al, and the Gabapentin Paediatric Study Group. Gabapentin as add-on therapy in children with refractory partial seizures: a 12 week, multicentre, double blind placebo controlled study. Epilepsia1999;40(8):1147-54. [PMID: 10448830]">Appleton 1999</a> who allowed three AEDs), the populations are likely to have a less drug‐resistant epilepsy. In addition, <a href="./references#CD001415-bbs2-0006" title="LindbergerM , AleniusM , FrisenL , JohannessenSI , LarssonS , MalmgrenK , et al, on behalf of the GREAT Study Investigators Group. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomised, double-blind, dose titration study. Epilepsia2000;41(10):1289-95. [PMID: 11051124]">Lindberger 2000</a> and <a href="./references#CD001415-bbs2-0007" title="SethiA , ChandraD , PuirV , MallikaV . Gabapentin and lamotrigine in Indian patients of partial epilepsy refractory to carbamazepine. Neurology India2002;50(3):359-63. [PMID: 12391470]">Sethi 2002</a> used a flexible dosing regimen, allowing doses of gabapentin to be increased as tolerated. This high flexibility made dose adjustments possible in response to a lack of seizure control, with doses of gabapentin 3600 mg/day allowed. This may be reflective of the increased efficacy of gabapentin at higher doses yet this flexible dosing method did result in complexity when interpreting the results as the final doses achieved to maintain seizure control have not been specified. At the other end of the spectrum in the <a href="./references#CD001415-bbs2-0005" title="LeachJP , GirvanJ , PaulA , BrodieMJ . Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry1997;62(4):372-6. [PMID: 9120451]">Leach 1997</a> study, despite allowing doses of gabapentin 2400 mg, only 2/23 (8.7%) participants achieved 50% or greater focal seizure control; this may be reflective of the small sample size and the cross‐over design. All participants received all doses (1200 mg, 1800 mg and 2400 mg) with a washout period of four weeks between doses; this dosing pattern may have influenced the efficacy of gabapentin, which may have resulted in period and carry‐over effects. </p> <p>Results for the outcome 'Treatment withdrawal' suggested that gabapentin was well tolerated, as there was no significant difference between gabapentin and placebo. However, the efficacy results suggested that optimal doses of gabapentin may not have been tested and it may well be that higher doses of gabapentin were less well tolerated. With respect to adverse effects, dizziness, fatigue and somnolence were significantly more likely to occur in the gabapentin‐treated group. There were insufficient data available for this review to delineate the precise adverse effect profile of this drug. </p> </section> <section id="CD001415-sec-0093"> <h3 class="title" id="CD001415-sec-0093">Overall completeness and applicability of evidence</h3> <p>The studies reviewed were all short duration and no conclusions could be drawn regarding the long‐term efficacy of gabapentin. One trial recruited children only (<a href="./references#CD001415-bbs2-0002" title="AppletonR , FichtnerK , LaMoreauxL , AlexanderJ , HalsallG , MurrayG , et al, and the Gabapentin Paediatric Study Group. Gabapentin as add-on therapy in children with refractory partial seizures: a 12 week, multicentre, double blind placebo controlled study. Epilepsia1999;40(8):1147-54. [PMID: 10448830]">Appleton 1999</a>), and the estimate for seizure reduction was low in that study. Caution is required when extrapolating the results of this trial to adults. </p> <p>In terms of seizure subtypes, <a href="./references#CD001415-bbs2-0007" title="SethiA , ChandraD , PuirV , MallikaV . Gabapentin and lamotrigine in Indian patients of partial epilepsy refractory to carbamazepine. Neurology India2002;50(3):359-63. [PMID: 12391470]">Sethi 2002</a> reported gabapentin's more pronounced effects on simple focal seizures and secondary generalised as opposed to complex focal seizures. This is contrary to the <a href="./references#CD001415-bbs2-0011" title="US Gabapentin Study Group No 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology1993;43(11):2292-8. [PMID: 8232945]">US Gabapentin 1993</a> study, which observed gabapentin to be more efficacious in complex focal seizures. This review focused on the use of gabapentin in drug‐resistant focal epilepsy and the results could not be generalised to add‐on treatment in people with generalised epilepsy. Likewise, no inference can be made about the efficacy and tolerability of gabapentin when used as monotherapy. </p> <p>The results of this review indicated that gabapentin was an effective add‐on treatment. We found three head‐to‐head trials with no study finding a significant difference between gabapentin and the alternative AED (pregabalin (<a href="./references#CD001415-bbs2-0004" title="FrenchJ , GlueP , FriedmanD , AlmasM , YardiN , KnappL , et al. Adjunctive pregabalin vs gabapentin for focal seizures: interpretation of comparative outcomes. Neurology2016;87(12):1242-9. [PMID: 27521437]">French 2016</a>), vigabatrin (<a href="./references#CD001415-bbs2-0006" title="LindbergerM , AleniusM , FrisenL , JohannessenSI , LarssonS , MalmgrenK , et al, on behalf of the GREAT Study Investigators Group. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomised, double-blind, dose titration study. Epilepsia2000;41(10):1289-95. [PMID: 11051124]">Lindberger 2000</a>), and lamotrigine (<a href="./references#CD001415-bbs2-0007" title="SethiA , ChandraD , PuirV , MallikaV . Gabapentin and lamotrigine in Indian patients of partial epilepsy refractory to carbamazepine. Neurology India2002;50(3):359-63. [PMID: 12391470]">Sethi 2002</a>)). As clinicians are faced with an ever increasing number of AEDs to choose from, more head‐to‐head trials are required to provide the evidence that is needed to enable clinicians to make an evidence‐based choice between AEDs. </p> <p>It remains difficult to predict the differences between a rapid and slow initiation of gabapentin, as the <a href="./references#CD001415-bbs2-0003" title="FisherRS , SachdeoRC , PellockJ , PenovichPE , MagnusL , BernsteinP . Rapid Initiation of gabapentin: a randomised control trial. Neurology2001;56(6):743-8. [PMID: 11274308]">Fisher 2001</a> study only observed the effects of rapid initiation on the first day of starting the maximum dose and four days later. However, they did contact participants for the subsequent two weeks to report any serious outcomes. These were not documented in the report; therefore, it is difficult to extrapolate data beyond this period. </p> </section> <section id="CD001415-sec-0094"> <h3 class="title" id="CD001415-sec-0094">Quality of the evidence</h3> <p>Seven out of the 12 studies used adequate methods of concealment of randomisation. All trials were double‐blind; however, often little information was reported as to how personnel/outcome assessors were blinded. For the studies included in the meta‐analysis, apart from <a href="./references#CD001415-bbs2-0012" title="YamauchiT , KanekoS , VagiK , SaseS . Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study. Psychiatry and Clinical Neurosciences2006;60(4):507-15. [PMID: 16884455]">Yamauchi 2006</a>, published reports referred to their analyses as being ITT, with 222/1688 participants recruited excluded from analyses. Reported analyses would perhaps be better called 'exploratory,' as participants who had treatment withdrawn during the treatment period and did not meet the original trial inclusion criteria were excluded from the reported analyses, despite completing the treatment period with adequate seizure data. </p> <p>Additional data, supplied by Parke Davis, revealed that 38 participants did not complete the treatment phase and nine had inadequate seizure data recorded, hence the percentage reduction in seizure frequency could not be calculated for 47 of these participants. <a href="./references#CD001415-bbs2-0012" title="YamauchiT , KanekoS , VagiK , SaseS . Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study. Psychiatry and Clinical Neurosciences2006;60(4):507-15. [PMID: 16884455]">Yamauchi 2006</a> stated that 19 participants were not included in the study and provided reasons for this. The <a href="./references#CD001415-bbs2-0004" title="FrenchJ , GlueP , FriedmanD , AlmasM , YardiN , KnappL , et al. Adjunctive pregabalin vs gabapentin for focal seizures: interpretation of comparative outcomes. Neurology2016;87(12):1242-9. [PMID: 27521437]">French 2016</a> study stated that 123 participants withdrew for any reason. Similarly, there was a high risk of attrition bias in the remaining studies, which we discussed in narrative form (<a href="./references#CD001415-bbs2-0003" title="FisherRS , SachdeoRC , PellockJ , PenovichPE , MagnusL , BernsteinP . Rapid Initiation of gabapentin: a randomised control trial. Neurology2001;56(6):743-8. [PMID: 11274308]">Fisher 2001</a>; <a href="./references#CD001415-bbs2-0005" title="LeachJP , GirvanJ , PaulA , BrodieMJ . Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry1997;62(4):372-6. [PMID: 9120451]">Leach 1997</a>; <a href="./references#CD001415-bbs2-0009" title="TomovicM , IlicT , MihajlovicM , JovicicA . Gabapentin as adjuvant therapy in the treatment of refractory partial epilepsy. Vojnosanitetski Pregled1999;56(2):151-6. [PMID: 10437420]">Tomovic 1999</a>), apart from <a href="./references#CD001415-bbs2-0006" title="LindbergerM , AleniusM , FrisenL , JohannessenSI , LarssonS , MalmgrenK , et al, on behalf of the GREAT Study Investigators Group. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomised, double-blind, dose titration study. Epilepsia2000;41(10):1289-95. [PMID: 11051124]">Lindberger 2000</a> for which analysis was completely ITT. <a href="./references#CD001415-bbs2-0007" title="SethiA , ChandraD , PuirV , MallikaV . Gabapentin and lamotrigine in Indian patients of partial epilepsy refractory to carbamazepine. Neurology India2002;50(3):359-63. [PMID: 12391470]">Sethi 2002</a> did not give any information related to dropouts and, therefore, the risk was uncertain. Selective outcome reporting bias was unclear in <a href="./references#CD001415-bbs2-0005" title="LeachJP , GirvanJ , PaulA , BrodieMJ . Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry1997;62(4):372-6. [PMID: 9120451]">Leach 1997</a>, <a href="./references#CD001415-bbs2-0006" title="LindbergerM , AleniusM , FrisenL , JohannessenSI , LarssonS , MalmgrenK , et al, on behalf of the GREAT Study Investigators Group. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomised, double-blind, dose titration study. Epilepsia2000;41(10):1289-95. [PMID: 11051124]">Lindberger 2000</a>, <a href="./references#CD001415-bbs2-0007" title="SethiA , ChandraD , PuirV , MallikaV . Gabapentin and lamotrigine in Indian patients of partial epilepsy refractory to carbamazepine. Neurology India2002;50(3):359-63. [PMID: 12391470]">Sethi 2002</a>, and <a href="./references#CD001415-bbs2-0009" title="TomovicM , IlicT , MihajlovicM , JovicicA . Gabapentin as adjuvant therapy in the treatment of refractory partial epilepsy. Vojnosanitetski Pregled1999;56(2):151-6. [PMID: 10437420]">Tomovic 1999</a>, as they mentioned 'seizure activity recorded' without details of the methodology. </p> <p>Overall, the certainty of the evidence for the outcomes was low to moderate due to potential attrition bias resulting from missing outcome data and imprecise results with wide CIs. Research is needed into the effects of the long‐term use of gabapentin and to compare gabapentin with other add‐on drugs. </p> </section> <section id="CD001415-sec-0095"> <h3 class="title" id="CD001415-sec-0095">Potential biases in the review process</h3> <p>There were discrepancies between study designs that may be reflected in the variability of the results. </p> <p>Parke Davis sponsored most of trials included in this review, apart from <a href="./references#CD001415-bbs2-0007" title="SethiA , ChandraD , PuirV , MallikaV . Gabapentin and lamotrigine in Indian patients of partial epilepsy refractory to carbamazepine. Neurology India2002;50(3):359-63. [PMID: 12391470]">Sethi 2002</a> and <a href="./references#CD001415-bbs2-0009" title="TomovicM , IlicT , MihajlovicM , JovicicA . Gabapentin as adjuvant therapy in the treatment of refractory partial epilepsy. Vojnosanitetski Pregled1999;56(2):151-6. [PMID: 10437420]">Tomovic 1999</a>. Pfizer Inc., the manufacturer of gabapentin and pregabalin, funded one trial (<a href="./references#CD001415-bbs2-0004" title="FrenchJ , GlueP , FriedmanD , AlmasM , YardiN , KnappL , et al. Adjunctive pregabalin vs gabapentin for focal seizures: interpretation of comparative outcomes. Neurology2016;87(12):1242-9. [PMID: 27521437]">French 2016</a>). </p> </section> <section id="CD001415-sec-0096"> <h3 class="title" id="CD001415-sec-0096">Agreements and disagreements with other studies or reviews</h3> <p>We found no reviews or published information on the use of gabapentin as add‐on therapy for drug‐resistant focal epilepsy. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001415-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/urn:x-wiley:14651858:media:CD001415:CD001415-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram. Date of search 11 August 2020. RCT: randomised controlled trial." data-id="CD001415-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_n/nCD001415-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_t/tCD001415-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram. Date of search 11 August 2020. RCT: randomised controlled trial.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/full#CD001415-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_n/nCD001415-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001415-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/urn:x-wiley:14651858:media:CD001415:CD001415-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001415-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_n/nCD001415-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_t/tCD001415-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/full#CD001415-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_n/nCD001415-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001415-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/urn:x-wiley:14651858:media:CD001415:CD001415-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001415-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_n/nCD001415-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_t/tCD001415-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/full#CD001415-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_n/nCD001415-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001415-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/urn:x-wiley:14651858:media:CD001415:CD001415-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Gabapentin versus placebo, outcome: 1.1 Reduction in seizure frequency 50% or greater." data-id="CD001415-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_n/nCD001415-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_t/tCD001415-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Gabapentin versus placebo, outcome: 1.1 Reduction in seizure frequency 50% or greater. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/full#CD001415-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_n/nCD001415-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001415-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/urn:x-wiley:14651858:media:CD001415:CD001415-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Gabapentin versus placebo, Outcome 1: Reduction in seizure frequency ≥ 50%" data-id="CD001415-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_n/nCD001415-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_t/tCD001415-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Gabapentin versus placebo, Outcome 1: Reduction in seizure frequency ≥ 50% </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/references#CD001415-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_n/nCD001415-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001415-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/urn:x-wiley:14651858:media:CD001415:CD001415-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Gabapentin versus placebo, Outcome 2: Treatment withdrawal" data-id="CD001415-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_n/nCD001415-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_t/tCD001415-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Gabapentin versus placebo, Outcome 2: Treatment withdrawal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/references#CD001415-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_n/nCD001415-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001415-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/urn:x-wiley:14651858:media:CD001415:CD001415-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Gabapentin versus placebo, Outcome 3: Adverse effects" data-id="CD001415-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_n/nCD001415-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_t/tCD001415-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Gabapentin versus placebo, Outcome 3: Adverse effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/references#CD001415-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/media/CDSR/CD001415/image_n/nCD001415-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001415-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Gabapentin versus placebo for people with drug‐resistant focal epilepsy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Gabapentin versus placebo for people with drug‐resistant focal epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with drug‐resistant focal epilepsy </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> gabapentin </p> <p><b>Comparator:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Gabapentin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction in seizure frequency of</b> ≥ <b>50%: primary analysis</b><br/>Number of seizures reported in seizure diary </p> <p>Follow‐up: 12–14 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 100</b><br/>(17 to 31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.89</b> <br/>(95% CI 1.40 to 2.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1206<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &gt; 1 indicated outcome was more likely in gabapentin group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment withdrawal</b><br/>Number of participants withdrawn for any reason </p> <p>Follow‐up: 12–14 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 100</b><br/>(8 to 15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b> <br/>(95% CI 0.74 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1206<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &gt; 1 indicated outcome was more likely in gabapentin group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: ataxia</b><br/>Number of participants experiencing ataxia </p> <p>Follow‐up: 12–14 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 100</b><br/>(5 to 20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.01</b> <br/>(99% CI 0.98 to 4.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>787<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &gt; 1 indicated outcome was more likely in gabapentin group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: dizziness</b><br/>Number of participants experiencing dizziness </p> <p>Follow‐up: 12–14 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 100</b><br/>(8 to 23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.43</b> <br/>(99% CI 1.44 to 4.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1206<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &gt; 1 indicated outcome was more likely in gabapentin group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: fatigue</b><br/>Number of participants experiencing fatigue </p> <p>Follow‐up: 12–14 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b><br/>(3 to 13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.95</b> <br/>(99% CI 0.99 to 3.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1161<br/>(5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &gt; 1 indicated outcome was more likely in gabapentin group.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: nausea</b><br/>Number of participants experiencing nausea </p> <p>Follow‐up: 12–14 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b><br/>(4 to 12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> <br/>(99% CI 0.52 to 1.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1034<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &gt; 1 indicated outcome was more likely in gabapentin group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: somnolence</b><br/>Number of participants experiencing somnolence </p> <p>Follow‐up: 12–14 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 100</b><br/>(9 to 23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.93</b> <br/>(99% CI 1.22 to 3.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1206<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &gt; 1 indicated outcome was more likely in gabapentin group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: headache</b><br/>Number of participants experiencing headache </p> <p>Follow‐up: 12–14 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b><br/>(3 to 10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.79</b> <br/>(99% CI 0.46 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1206<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &lt; 1 indicated outcome was more likely in control group.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for risk of bias: four studies had missing data and did not carry out intention‐to‐treat analysis. Best‐case and worst‐case scenario analysis demonstrated that missing data may have impacted on the size of the true treatment effect.<br/><sup>b</sup>Downgraded once for risk of bias: three studies had missing data and did not carry out intention‐to‐treat analysis.<br/><sup>c</sup>Downgraded once for imprecision: one study with small number of effects and wide confidence intervals; concern regarding the confidence in overall effect.<br/><sup>d</sup>Downgraded once for imprecision: two studies with small‐study effects and wide confidence intervals; concern regarding the confidence in overall effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Gabapentin versus placebo for people with drug‐resistant focal epilepsy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/full#CD001415-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001415-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Estimated percentage responders and percentage difference compared to placebo per gabapentin dose, intention‐to‐treat</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% Responders (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% Difference (95% CI) compared to placebo</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 mg (placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7 (7.2 to 12.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6 (11.4 to 16.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9 (1.6 to 6.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>900 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.0 (13.7 to 18.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.3 (2.8 to 9.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.7 (15.8 to 22.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.0 (4.4 to 13.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1800 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.3 (19.3 to 32.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.5 (8.5 to 22.5)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>CI: confidence interval.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Estimated percentage responders and percentage difference compared to placebo per gabapentin dose, intention‐to‐treat</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/full#CD001415-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001415-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Estimated percentage responders and percentage difference compared to placebo per gabapentin dose, best‐case</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Responders % (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% Difference (95% CI) compared to placebo</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 mg (placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.9 (8.1 to 14.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.2 (14.6 to 20.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.3 (3.9 to 8.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>900 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.4 (18.5 to 24.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.5 (6.8 to 14.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.2 (22.4 to 30.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.3 (10.3 to 20.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1800 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.6 (30.0 to 46.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.7 (19.3 to 34.2)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>CI: confidence interval.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Estimated percentage responders and percentage difference compared to placebo per gabapentin dose, best‐case</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/full#CD001415-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001415-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Estimated percentage responders and percentage difference compared to placebo per gabapentin dose, worst‐case</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Responders % (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% Difference (95% CI) compared to placebo</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 mg (placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.8 (10.4 to 18.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.4 (13.8 to 19.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 (–0.3 to 5.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>900 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.8 (15.3 to 20.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9 (–0.3 to 8.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.2 (16.2 to 22.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.4 (–0.2 to 11.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1800 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.5 (17.1 to 29.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.6 (0.3 to 17.0)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>CI: confidence interval.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Estimated percentage responders and percentage difference compared to placebo per gabapentin dose, worst‐case</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/full#CD001415-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001415-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse effects Fisher 2001</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse effect</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Slow initiation (day 2)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rapid initiation (day 2)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Slow initiation (day 7)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rapid initiation (day 7)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>%</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Fatigue</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/280</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/294</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/274</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/294</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dizziness</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/280</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/294</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45/276</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59/293</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.1</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Somnolence</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/280</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/294</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/275</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/293</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.6</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ataxia</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/280</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/294</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/275</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/294</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse effects Fisher 2001</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/full#CD001415-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001415-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Gabapentin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Reduction in seizure frequency ≥ 50% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Primary analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [1.40, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Sensitivity (best‐case)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.52 [1.89, 3.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Sensitivity (worst‐case)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.04, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Treatment withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.74, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Ataxia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [0.98, 4.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.43 [1.44, 4.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [0.99, 3.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.46, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.5 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1034</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.52, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.6 Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [1.22, 3.06]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Gabapentin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001415.pub4/references#CD001415-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001415.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD001415-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001415-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001415-note-0009">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD001415-note-0010">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001415\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001415\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001415\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001415\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001415\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001415\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001415\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001415\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001415\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001415\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001415\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001415\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001415\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001415\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001415\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001415\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001415\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001415\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=EBp84H4P&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001415.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001415.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001415.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001415.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001415.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728669954"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001415.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728669958"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001415.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eca25dba8f56f',t:'MTc0MDcyODY3MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 